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Abstract
The incapacity to generate a sufficient number of mAbs to conduct large-scale analyses 
remains one of the most serious limitations in the field of functional genomics. Current 
methods of mAb production are very labour intensive and disappointingly low through­
put, with a per capita production level of about 20 antigens per year. Here we present 
a modified hybridoma production method incorporating a novel screening assay which 
can be scaled up to generate antibodies in sufficient quantities for proteomics-scale 
analysis. Our method circumvents previous obstacles to increasing the throughput 
level of mAb production, in two ways. First, by immunizing a single mouse with mul­
tiple target antigens, we dramatically reduce the number of tissue culture operations 
normally necessary for performing multiple fusions simultaneously using only one anti­
gen per animal. This minimises tissue culture operations and results in hybridomas 
that secrete antibodies specifically recognizing each of the target antigens. Second, 
we developed a novel antigen microarray assay (HybriChip) to screen supernatants 
generated by large-scale production. In this assay, an antigen chip is generated by 
coating an aminosilane treated slide with a single target antigen. Hybridoma culture 
supernatants from a fusion are consolidated and spotted as a microarray onto the 
antigen chip. After probing with a suitable fluorescently labelled secondary antibody, 
positive hybridomas are identified in a microarray scanner. The isotype of the bound 
antibody can be concomitantly determined by probing the antigen chip with mixtures of 
isotype-specific secondary antibodies, such as Cy5 -conjugated anti-mouse IgM and 
Cy3-conjugated antimouse pan-IgG (recognizing all mouse IgG isotypes). Different 
antigen chips can simultaneously be spotted in parallel with the same hybridoma cul­
ture supernatants, allowing rapid automated assay of multiple antibodies against many 
target antigens.
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1 INTRODUCTION
1 Introduction
1.1 Proteomics
1.1.1 Conventional proteomic analysis tools
When the journal Science published, in 1995, the first paper describing the use of 
chemically modified glass slides to immobilse several different species of cDNAs (Schena 
et al., 1995), a new era began for biological research. While DNA microarrays were 
becoming common tools in genomic research, for example aimed at the study of differ­
ential gene expression, the field of proteomics had no such high-throughput analysis 
tools for the study of proteins at a global level. However, the combination of two dimen­
sional gel electrophoresis (2D PAGE), mass spectrometry (MS) and yeast-two-hybrid 
(Y2H) approaches for the study of protein-protein interactions and protein profiling, 
together with other novel methods for the isolation and analysis of native protein com­
plexes, such as the Tandem Affinity Purification (TAP) (Rigaut et at., 1999), had demon­
strated the impact of proteoomic analyses in the post-genomic era (Naaby-Hansen 
et al., 2001).
2D PAGE is being extensively used as a primary tool for the separation and visualiza­
tion of cellular protein pools. Carrying out a double separation of a pool of proteins by 
first a separation (in the horizontal dimension) based on isoelectric focussing, followed 
by a standard SDS-PAGE (O’Farrell et al., 1977), 2D PAGE allows for the separation of 
thousands of proteins. This technique allows for comparative proteomic experiments 
such as studying variations of protein levels in ’’healthy” and "diseased” tissues. This 
can be done using double-labelling systems, such as for isotope-coded affinity tags 
(l-CAT), or a Cy3/Cy5 combination of fiuorophores for the two samples to be analysed 
(Gygi et al., 1999, 2000; Naaby-Hansen et al., 2001), or by direct superimposition of 
the 2D PAGE profiles. However, 2D PAGE can not be defined as a "user friendly” tech­
nique since it is time consuming, non-trivial to carry out, not 100% reproducible, and is 
not truly compatible for insoluble or low-abundant proteins.
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Mass spectrometry has been widely used for the identification of proteins and for the 
study of protein-protein interactions. Starting from the 1980s and, more significantly 
during the 1990s, MS has become a crucial tool in biological research and is used in 
a wide range of applications, from protein/peptide sequencing (MS/MS) to the iden­
tification of single protein species in heterogeneous samples . Prior to the MS anal­
ysis, the proteins are usually cleaved using endoproteases, such as trypsin, to ob­
tain peptides. These resulting fragments are electrically charged and brought to a 
gaseous phase by the mass spectrometer. Charged peptides are directed to a detec­
tor via an electric field and their time of flight (TOP) is this measured. Peptides with 
a lower mass-over-charge ratio (m/z) will travel faster than peptides with higher m/z, 
thus allowing for an identification of the mass of each single peptide when correlated 
to standard calibration peptides. Other detection methods that use the charge, or other 
physical properties of the peptides to determine the m/z value of each protein frag­
ment are available and the combination of different methods in single MS machines 
allow for the design and execution of a great variety of experiments. The identifica­
tion of proteins is done by analysing either sets of detected peptide masses (pep­
tide fingerprint) and/or from partial sequence information, using bioinformatics tools 
and databases, such as MASCOT/MOWSE (http://www.matrixscience.com/)(Yates, 
1998; Godovac-Zimmermann and Brown, 2001 ; Mann et al., 2001).
The coupling of techniques such as 2D PAGE and protein separation methods (like 
the TAP strategy and/or HPLC systems), has facilitated significant advances in the 
field of proteomic analysis. For example, it has been possible to isolate and identify 
large complexes and protein networks and to identify novel or differentially regulated 
proteins (Gavin et al., 2002). However, even though such advances have allowed for 
an increased throughput in proteomics, the currently available techniques are difficult 
to implement, since they require highly specialised researchers. Therefore, fast, cheap 
and efficient techniques, which could facilitate a high-throughput protein analysis are 
needed as alternatives to the current available analysis tools.
F. De Masi 15 9606101
1 INTRODUCTION
1.1.2 Protein microarrays
The concept of "protein microarray”, and more precisely "antibody microarray”, was first 
introduced by Roger Ekins when he proposed the idea of miniaturizing ligand binding 
assays to enable a simultaneous ultrasensitive measurement of many analytes 
in the same sample [...]” (Ekins, 1998). This report presented a precise description 
of how an antibody microarray would be generated and analysed, laying the building 
foundations for this novel technology.
Ekin’s theories, combined with the potential impact that protein arrays could have in 
the fields of bio- and pharmacological research, lead several labs in the development 
of protein microarrays. Initially, proteins were arrayed onto membranes, or microtiter 
plate-based assays were developped to generate low-density protein arrays (Cahill, 
2001). These developments allowed researches to perform large scale protein screens 
(usually around 4-500 proteins at a time) in a single-step procedure (Joos et al., 2000; 
de Wildt et al., 2000; Lueking et al., 1999). The possibility of using glass slides for 
arraying proteins was being heavily considered. However, the common belief was 
that proteins were not compatible with a DNA microarray equivalent because of their 
assumed instability and degradation if attached on a glass slide.
This view predominated until September 2000, when the journal Science published 
the first report of a functional protein microarray, in which small sets of proteins were 
attached and detected on a dry solid support (MacBeath and Schreiber, 2000). The 
authors presented several experiments where antibodies, antigens or substrates were 
attached to glass slides. The interactions of the immobilized samples with their binding 
partners were detected using a strategy similar to the one used for DNA microarrays. 
Soon after, Haab and coworkers (Stanford, USA) showed that, similarly to DNA mi­
croarrays, arrays of 115 immobilized antigens or antibodies could be made to specifi­
cally detect their cognate ligands in heterogeneous solutions (Haab et al., 2001).
Taken together, these reports opened the field of using microarrays for proteomic 
projects. From that point, an increasing number of possibilities have emerged for the
F. De Masi 16 9606101
1 INTRODUCTION
use of microarrays, including diagnostic applications, antibody screening and protein- 
protein interactions (Zhu et al., 2001). Figure 1 gives an overview of the currently 
reported applications of protein microarrays. Dependent on the biological questions 
to be addressed, microarrays can present immobilized molecules such as antibodies, 
peptides, carbohydrates or small molecules. The applications, advantages and disad­
vantages of the different types of microarray approaches are summarised in Table 1 
(Zhu et al., 2003).
Protein Probe
\
Protein Antibody ^Vntigen Allergen Peptide Aptamer Small Mole Carbohydrate
Figure 1. Applications for protein microarrays.
Ligands, such as proteins, peptides, antibodies, antigens, allergens and small molecules 
are immobilized in high density on modified surfaces to form functional and analytical pro­
tein microarrays. These protein microarrays can also be used for various kinds of bio­
chemical analyses.
Reprinted, with permission, from the Annual Review of Biochemistry, Volume 72 ©  2003 by Annual Reviews 
(www.annualreviews.org)
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Table 1. Comparison of different technologies for interaction proteomics
Reprinted, with permission, from the Annual Review of Biochemistry, Voiume 72 ©  2003 by Annuai Reviews 
(www.annualreviews.org)
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1.1.3 Advantages of protein microarrays
Compared to other protein analysis tools, protein microarrays present several advan­
tages. First of all, the possibility of immobilizing several thousands of molecules in de­
fined areas of a small solid support allows for the design of complex experiments that 
would have been unrealistic to carry out using conventional methods. This facilitates 
large scale proteomics experiments where extensive libraries of proteins are simultane­
ously probed in one single experiment. This advantage was demonstrated by Snyder’s 
group (Yale, USA), which identified novel calmodulin and phospholipid binding proteins 
using a microarray containing an almost complete yeast proteome (Zhu et al., 2001). 
The idea behind these two experiments was to express and purify the whole yeast pro­
teome, immobilise each protein on a modified microscope glass slide and probe this 
array with labelled calmodulin and phospholipids. This group used an identical strategy 
to analyse the properties and substrates of several kinases (Zhu et al., 2000). In this 
experiment, phosphorylation by the kinases were detected by adding ^ -^yATP into the 
kinase reaction buffers and detecting the incorporation of radioactive phosphate into 
the immobilized substrates using a phosphoimager. Since the microarrays contained 
4800 proteins in duplicate, such experiments could not have been performed using 
conventional methods.
Another important advantage of protein microarrays is the low amounts of reagents 
and sample required for the production of reliable data. It has been shown that immo­
bilized antigens and antibodies can be accurately detected via their specific interaction 
partners at concentrations as low as 1.6 and 0.34 /ig.ml” \  respectively (Haab et al.,
2001). Microarray spotters are able to dispense minute volumes of reagents per spot 
(in the range of hundreds of picoliters) and an entire microarray can be hybridized with 
a total volume as low as 25 / j \ .  Therefore, the absolute amounts of sample required 
to carry out a microarray experiment are very low. This particular property of protein 
microarrays is crucial, especially in experiments aimed at studying low abundance or 
difficult-to-produce proteins.
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Protein microarrays allow for multiplexed experiments, where multiple samples are 
analysed simultaneously. Similarly to DNA microarrays, where it is possible to anal­
yse in a genome wide manner the patterns of gene expression, protein microarrays 
can be used to analyse variations in cellular protein composition. This can be done by 
differentially labelling sets of samples derived from tissues grown under different condi­
tions or from different cellular compartments. These differentially labelled samples can 
then be studied in parallel, and the microarray is analysed under different wavelengths, 
specific for each label used. This approach could prove essential in the study of cellular 
events following treatment of tissues with specific stimuli or under different pathological 
conditions. However, such a comparative analysis is still hampered by the lack of suit­
able hardware. The conventional tools used to produce and analyse protein microar­
rays are usually those designed for DNA microarray experiments, where usually only 
two fiuorophores (Cy3 and Cy5) are used. Fortunately, "new-generation" multi-laser 
and multi-filter scanners (for example the LS400 from Tecan and the GenePix4200 se­
ries from Axon Instruments) are offering the possibility to detect several fiuorophores 
in single experiments, because of the incorporation of multiple excitation lasers and 
emission filters.
The use of protein microarrays as diagnostic tools, especially in the fields of cancer and 
immune diseases, is an example of applications benefitting from of all of the advanta­
geous features of protein microarrays as outlined above. The immobilization of several 
antibodies specific against defined disease markers, has allowed for a one-pass profil­
ing of tissue samples with a high sensitivity and specificity, showing that the sensitivity 
and multiplexing nature of protein microarrays can be successfully applied for the de­
tection of diseases (Paweletz et al., 2001; Robinson et al., 2002; Joos et al., 2000; 
Lin et al., 2003; MacBeath, 2002). A significant feature, from a clinical point of view, is 
that diagnostic microarrays require very low sample amounts (a few microliters of blood 
are usually sufficient), whereby the physical and psychological stress on patients to be 
diagnosed can be dramatically reduced.
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1.1.4 Disadvantages of protein microarrays
One of the major bottlenecks in the use of protein microarrays in global protein analy­
sis is the availability of samples. Whether it is proteins, peptides, antibodies or small 
chemical compounds, the availability of ready-to-use molecules is a major problem. 
For example, the majority of the commercially available reagents are not compatible 
with protein microarray applications: purified proteins often come already bound to 
beads, coupled with detection reagents or diluted in specific buffers. Alternatives to 
commercially available products are self-produced samples. However, self production 
of proteins/peptides/antibodies is a long and tedious process that usually requires spe­
cialised staff, working full-time on such projects. Difficulties in obtaining the required 
samples for microarray applications is a serious limiting factor for large scale proteomic 
projects. As an example, Snyder’s group (Yale, USA) spent between 4 and 5 years to 
clone, express and purify the yeast proteome (Snyder, personal communication). The 
problems involved in obtaining the required number of samples leads to increasing dif­
ficulties in the design and implementation of large scale microarray projects. Under 
the guidance of the Human Proteome Organisation (http://www.hupo.org) and other 
Societies, several consortia are now being established in order to overcome these lim­
itations.
The stability and activity of the attached molecules is an inherent issue of concerns 
when using protein microarrays, since the conditions for an attached protein to remain 
native might differ from those of its neighboring samples. Fortunately, it appears that 
proteins are able to maintain a good level of folding even after drying on the slide 
(MacBeath personal communication and my personal observations). However, the 
activity of proteins is more difficult to maintain, since the experimental conditions in 
protein microarrays applications are far from being physiological (immobilized molecule 
on a dry glass surface). In addition, due to the high density, the heavy miniaturization 
and the low sample amounts of the array, it is not possible to analyse the state of each 
immobilized sample.
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A major disadvantage of protein microarrays is the inability to identify the proteins cap­
tured by immobilized Interaction partners from a mixture of unknown molecules. Thus, 
protein micro array analyses are still limited to known samples and events. It is for in­
stance impossible to identify interaction partners of immobilized proteins and peptides 
within a cell lysate, For this to be possible, the porting of MS technology to microar­
rays is required. One such technology is currently available. Ciphergen has produced 
the ProteinChip/SELDI-TOF system, which is based of an array of 8 spotted samples. 
Following binding of interaction partners, this array directly serves as a platform for 
ionization in the SELDl-TOF, allowing for the bound analytes to be identified. This 
technology has been very useful for protein profiling in cancer, but it still limited to a 
few samples per experiment (Fung et al., 2001 ; Petricoin et al., 2002). There Is a cur­
rent drive into developing novel protein microarrays, which can be directly coupled to 
MALDI-MS (Scrivener et al., 2003), but this field is still in an exploratory phase.
1.1.5 Labelling and detection strategies in protein microarrays analysis
One major aspect for the successful application of protein microarrays is the strategy 
adopted to detect an interaction between an immobilized unit and its interaction part­
ner. This is done by the labelling of the hybridisation probe with fiuorophores or other 
signal emitting compounds. Because of the varied properties of proteins and of their 
interactions, different labelling and detection strategies have been designed. The four 
most used strategies are discussed in this chapter (Fig 2).
First, detection based on the direct labelling of the probe is a very common strategy. 
This requires the prior attachment of labelling reagents, such as fiuorophores or ra­
dioactive compounds, to the probe (Fig 2 A). This method allows for the direct de­
tection of the bound probe to its immobilized interaction partner (Haab et al., 2001; 
MacBeath and Schreiber, 2000; Martin et al., 2003). In case of the probe being a 
purified molecule, this method can, in addition, generate semi-quantitative read-outs. 
However, this does not apply when complex mixtures of proteins are labelled, since
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each probe in the mixture presents different biochemical properties, resulting in differ­
ent numbers of labelling moieties per probe. Therefore, unless each molecule in the 
solution is individually analysed, it would be impossible to quantify the levels of each 
component within the mixture, thus making a quantitative, or semiquantitative, analysis 
impossible. Detection strategies based on direct labelling of the probe present some 
potential drawbacks, since the labelling reaction is done at the level of single amino- 
acids. For example, there is an intrinsic risk of incorporating a label molecule into the 
protein’s binding domain, or catalytic region, reducing the interaction’s affinity with the 
immobilized sample.
A second widely used method is indirect labelling of the interacting protein pair. This 
strategy is similar to a Western blot procedure in which the probe, bound to its immo­
bilized interaction partner, is detected by a specific antibody labelled with a detection 
reagent (HRP, fluorophore, etc) (Fig. 2 B). In this experimental setup, no labelling 
reagents can interfere with the binding reaction. It requires, however, the availability of 
highly specific antibodies.
A third strategy, the "sandwich assay", is often applied for the specific detection of target 
proteins (Fig. 2 C). In this method, an array of antibodies is hybridised with an antigen 
and this antibody-antigen interaction is detected by a labelled second antibody, which 
is specific for a different epitope of the antigen. This approach requires the availability 
of two high affinity antibodies that are specific for different epitopes in the antigen. This 
system is widely used in diagnostics such as cytokine profiling, since this field benefits 
from the availability of such specific antibody pairs (Huang et al., 2001; MacBeath,
2002).
A fourth detection method, which combines several of the advantages of the previous 
methods is shown in figure 2 D. In this set-up, the screening probe is presented as a 
fusion protein, for example coupled to a biotin molecule. After the binding reaction is 
achieved, a labelled streptavidin molecule is then allowed to bind the biotin associated 
with the hybridisation probe. This strategy allows for a highly specific detection (since 
the biotin-avidin interaction is highly specific and strong) and has been used to identify
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the interactions of calmodulin against the complete yeast proteome (Chalet and Wolf, 
1964; Zhu et al., 2001). It has also been applied in the study of cytokines (Lin et al.,
2003). The fusion of light emitting proteins such as G FP to the probe, has also been 
used as a detection system in cell microarray experiments (Ziauddin and Sabatini, 
2001).
Other methods for the labelling and detection of probes have been proposed, but seem  
to be limited to highly specific applications. It has been proposed, for example, to label 
proteins with Europium chelates that can be detected using specific scanners (Scorilas 
et al., 2000). Also, novel reagents have been developed to detect phosphorylated sub­
strates in microarray based kinase assays. For example, a fluorescent Pro-Q Diamond 
phosphosensor dye technology has been developed by Molecular Probes (USA). This 
dye allows for the specific labelling of phosphorylated proteins, thus eliminating the 
requirement of 7 ^^  and 7 ^^-ATP from kinase experiments (Martin et al., 2003).
A. B. C. D.
Antigen 4 Anti mouse IgGY mAb ipecific to epitope 1 Fluophore
Y mAb specific to epitope 2 StreptavidinBiotin
Figure 2. Detection approaches in protein microarrays
A - Direct detection 
B - Indirect detection 
C - Sandwich assay 
D - Affinity detection
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Detection strategies for the analysis of protein interactions is fundamental in all fields 
of the life sciences, including biomedical research and proteomics. There is therefore 
a high requirement for specific, high affinity detection reagents. Monoclonal antibodies 
are particularly valuable reagents for these experiments. Since their first description 
in 1975 (Kohler and Milstein, 1975), monoclonal antibodies have proven to be very 
powerful reagents for the detection of proteins.
1.2 Monoclonal Antibodies
The technique for the production of monoclonal antibody secreting hybridomas (Koh­
ler and Milstein, 1975), has provided the life-sciences community with a revolution­
ary tool for the characterization, localization and manipulation of proteins and protein- 
complexes. With the advent of functional genomics and proteomics, the need for de­
tection reagents, such as monoclonal antibodies, has spectacularly increased. Un­
fortunately, conventional monoclonal antibody production methods have failed to keep 
up with such a demand, and the lack of monoclonal antibodies is now a significant 
bottleneck in all fields of biomedical research. The protocols used to generate mono­
clonal antibodies have hardly been modified since their first publication, 29 years ago. 
Monoclonal antibody production is comprised of three distinct steps:
1. Immunization of (usually) a mouse with an antigen
2. Cell culture: somatic fusion of harvested splenocytes from the donor animal to a 
myeloma cell-line using the fusogen polyethylene glycol (PEG) and subsequent 
tissue culture
3. Screening of the produced culture supernatants against the target protein. Posi­
tive clones are then subject to rounds of subcloning at limiting dilution to ensure 
monoclonality.
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The main limiting factors in this procedure are the cell culture steps and the screen­
ing of the hybridoma library generated at each fusion. Cell culture routines, including 
the fusion step, are extremely time consuming and require a lot of handling and are 
prone to human error. Generally, one person can generate highly specific, high-affinity 
monoclonal antibodies against 25 - 30 antigens per year. The conventional screen­
ing of the hybridoma libraries is generally performed by ELISA. This method is not 
a highly efficient screening platform, since it is time consuming and requires a lot of 
handling and reagents. In order to screen large libraries, containing thousands of sam­
ples, extensive automation is required to perform such a high scale range of ELISA 
screens. Thus, conventional monoclonal antibodies production methods are not suit­
able for high-throughput applications.
It has been recently stated that " ...Antibodies are the most prominent capture 
moiecules used to identify targets. Owing to the iabour intensive nature of 
monocional antibody production, however, the development of other aiternatives 
has become crucial..." (Templin et al., 2002). Other techniques which are truly high- 
throughput in their approach, such as phage-display, suffer from qualitative limitations, 
most notably low binding affinity. Antibodies generated by phage-display often require 
further molecular engineering to produce multi-use reagents, and are therefore not 
currently amenable to high throughput approaches (Irving et al., 1996; D’Mello and 
Howard, 2001; Gram et al., 1992). Alternatively, novel detection reagents have been 
developed and implemented in current research, such as aptamers, recombinant anti­
bodies and affibodies (Ronnmark et al., 2002a; Nord et al., 2001 ; Gunneriusson et al., 
1999; Hansson et al., 1999; Eklund et al., 2002; Brody et al., 1999; Bock et al., 1992; 
Knappik et al., 2000; Rônnmark et al., 2002b). However, these alternatives present 
limitations in the form of long selection processes and molecular engineering.
The establishment of ameliorated and more efficient protocols for the generation and 
screening of monoclonal antibodies is an important requirement in current research, 
and would allow for the generation of more complex collections of monoclonal antibod­
ies. This would bring a new level of biomedical research, allowing for the establishment
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of large scale proteomics projects.
1.3 Aims of project
1.3.1 Establishing a protein chip platform
At the beginning of this PhD project, protein microarray technology was a novelty, as 
only two papers reporting the use of protein microarrays on glass surfaces had been 
published (MacBeath and Schreiber, 2000; Haab et al., 2001). The first part of this 
project was aimed at establishing protocols and procedures that would allow the pro­
duction of functional and reliable protein microarrays. The main factors that had to be 
established in order to obtain such a platform were:
• Substrate chemistry: which chemical modifications of the glass slide were most 
suitable for the attachment of proteins?
e Spotting conditions: which physical parameters should be used to successfully 
array sets of proteins?
• Labelling and detection strategies: which strategies would be more suitable for 
the applications we wanted to design?
The initial aim was to establish these basic required conditions for the generation of 
functional protein microarrays. Having done this, the following goal was to design 
novel biological applications using protein microarrays, demonstrating the impact of 
this technology in proteomic research.
1.3.2 Development of a high-throughput screening method for the detection of 
monoclonal antibodies
Concurrently with the beginning of this PhD project, the EMBL had established a Mon­
oclonal Antibodies Core Facility (MACF). This faciiity was set up to meet the increasing
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need for the establishment of novel and more efficient protocols for the production and 
screening of monoclonal antibodies, in order to accelerate the setup of large scale 
proteomics projects.
The initial strategy of this facility was to test the possibility of implementing multiplex­
ing immunizations (ie, the simultaneous injection of several unrelated antigens into 
a single mouse), automated fusion and cell culture procedures and, as a screening 
technology, an automated ELISA procedure, using a dedicated custom built robotic so­
lution. However, this screening approach was early on found to be complicated and 
not economically viable. Therefore, the MACF needed to develop a novel screening 
method that would allow for an increased throughput and lower costs, compared to the 
planned automated ELISA platform.
Together with the MACF, I sought to devise a novel hybridoma screening approach 
using protein microarrays. The aim was to develop a rapid, efficient and cost effective 
way to screen thousands of hybridomas for specificity, within a single experiment.
1.3.3 Development of a protein microarray-specific analysis software
After having established the protein microarray platform and designed a novel mono­
clonal antibodies screening platform, it became clear that the available chip analysis 
software available was not satisfactory for the analysis of protein microarrays. Because 
of the short history of protein microarrays, all data analysis involving this technology 
is currently performed using software developed for the analysis of DNA microarrays. 
Such software packages are optimised for DNA microarrays experiments, and focus 
on statistical analyses of gene expression patterns, whereas only a few of the present 
features by these applications are useful for protein microarrays. Therefore, a third 
aim of this project was to write an analysis software, which specifically analyses those 
parameters needed for protein microarrays.
The specific goal was to create an analysis software that would allow for:
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• Creation of unique sample names to each sample in the array
• Mapping of the coordinates of each sample from its location in the cell culture 
plates
• Retrieval of meaningful data from the chip analysis
• Normalization of the data
• Analysis of the data and identification of positive samples
• Cross-experiment filtering (removal of false positives and cross reactive species)
• Population of a LIMS database (Laboratory Information Management Systems), 
where all data relative to each experiment is stored
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2 List of abbreviations
2-1 Buffers and Chemicals
• PBS: Phosphate Buffered Saline 
PBS-T: Phosphate Buffered Saline - Tween20 
TPBS: PBS, 0.1% TritonXlOO 
BRB80: Brinkley BR buffer 1980 
PFA: Paraformaldehyde 
GA: Glutaraldehyde 
AH: Azaserine Hypoxanthine 
HOF: Hybridoma Cloning Factor
2.2 Terminology
• mAb(s): Monoclonal antibody(les)
• HS(s): Hybridoma supernatant(s)
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3 Materials and Methods
3.1 Materials
3.1.1 Chemicals
• poly-i-Lysine (P8920); Casein (C3400); BSA (A3803); Sodium Azide (S8032), 
Ribi (M6536), Azaserine Hypoxanthine (A9666), OP! media supplement (05003), 
p-nitrophenyl phosphate (N7653): Sigma Aldrich
.  Cy3-Cy5 (PA25001), ECL (RPN2209): Amersham
• SuperSignal West Femto Maximum sensitivity substrate (34095): Pierce 
e Alum (77161T): Pierce
• Immuneasy (303101): Qiagen
• FBS (SH30070.03): Hyclone
• Hybridoma Cloning Factor (ECO1021N): Euroclone
3.1.2 Microarray Slides
• GoldSeal (3010): Gold Seal Products
• Standard Glass Slides: Menzel-Glaser
• FAST (10484182); CAST (10484181): Schleicher & Schuel
• HydroGel (6050017): Perkin Elmer
• SuperAmine (SMM); SuperAldehyde (SMA): Telechem Array-it
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CodeUnk (300011-4PK): Amersham
PicoSlides (PS-ITC-20): PicoRapid
• eSurf (MA0110): LifeLineLab
3.1.3 Antibodies
• a-Tubulin Clone DM1A (T9026); Protein A Clone SPA-27 (P2921); FLAG Ml 
(F3040): Sigma Aldrich
• kBe(sc-7275); kB a  (H4) (sc-1643); kB a  (C l5) (sc-203); M ip la (sc-1381); GST 
(sc-138); Fractalkine (sc-7226); His-Tag (sc-8036); p52 (sc-7386); p65 (sc-372); 
p53 (sc-6243); kB  (sc-9130): Santa Cruz Biotechnologies
• Cy3-conjugated goat anti-mouse IgG (115-165-164); Cy5-conjugated goat anti­
mouse IgM (115-175-020), Alkaline Phosphatase goat anti-mouse IgG+IgM (115- 
055-044): Jackson Immuno Research
3.1.4 Purified Proteins
kBe(sc-4328 WB); c-Rel (sc-4030); p52 (sc-4095); HI (sc-8030): Santa Cruz 
Biotechnologies
Protein A (539203): Calbiochem
Protein G (P5170); Human IgG (12511): Sigma Aldrich
All antigens received from internal and external research laboratories
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3.1.5 Consumables
• Micro Bio-Spin Chromatography Columns: BioRad
• Microcon 10 Centrifugal Filter Units: Millipore
3.1.6 Robots and electronic equipment
• Spotters: GMS416 (Affimetrix); Omnigrid (GeneMachines) ; MicroGrid (Apogent- 
Discoveries)
• Scanners; GMS418 (Affimetrix); GenePix 4.1 (Axon Genomics); LS400 (Tecan); 
Biomolex (Biomolex); Magellan (Tecan)
• Robots: Biomek FX (Beckman); TECAN Custom Setup
• Others: Lab-on-a-Chip (Agilent)
3.1.7 Buffers
• Cleaning Buffer A: 35 g NaOH, 140 ml H20, 210 ml 96% Ethanol
• poly-L-lysine solution: 25 ml poly-L-lysine, 280 ml ddH20, 25 ml PBS
• BRB80: As much as 80 mM of K-PIPES (pH 6.8), 1 mM MgCI, and 1 mM EGTA, 
titrated to pH 6.8 with KOH.
• HM20: DMEM, 20% FBS, Gentamycin, L-Glutamine
• Hybridoma Selection Medium: HM20, 10% HCF, 2% AH, 1% OPI
• Hybridoma Growth Medium; HM20, 10% HCF
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3.1.8 Blocking Solutions
• 3% Skimmed Milk in PBS-T (0.1 %)
.  3% Skimmed Milk, 0.02% Sodium Azide in PBS-T (0.1%) 
.  1% BSA In PBS 
.  3% BSA in PBS 
.  2.5% Casein in PBS
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3.2 Methods - initial experiments
3.2.1 Poly-L-Lysine coating
Poly-L-lysine coating of slides was performed according to the Stanford protocol (h ttp  : 
//cmgm.Stanford.edu/pbrown/protocols/l_slides.html).
Gold Seal slides were cleaned in Cleaning Buffer A overnight, with constant shaking. 
Slides were rinsed in ddHgO to remove traces of ethanol and NaOH. Clean slides were 
then incubated in the poly-L-lysine solution for 2 hours, at RT. After a further round of 
washes, the coated slides were centrifuged at 650 rpm for 5' to remove traces of liquid 
and then baked at 45°C for 10’.
3.2.2 Aminosilane coating: EMBL protocol
Protocols and guidelines for the production of EMBL’s aminosilane proprietary slides 
can be obtained from the patent application "Immobilisierung und Markierung von 
Biopolymeren" (DE10016073A1, publication date: March 1st, 2001).
The following protocols ("Preparation and spotting of baits”, "labelling of probes” and 
"hybridization”) were obtained from previously published data (MacBeath and Schreiber, 
2000; Haab et al., 2001).
3.2.3 Preparation and spotting of baits
All samples to be spotted were transferred into a glycerol free PBS solution using 
BioRad BioSpin P6 columns. Samples were spotted either manually (0.2 1^) using 
a Gilson pipette or robotically, using a microarrayer. The location of the spots was 
marked on the back of the slide using a diamond pencil, since once dried, the spots 
tend to become invisible. Dried chips were stored at 4*^ C in a sealed box. Before usage 
of the spotted arrays, these were quickly rinsed in a 3% skimmed milk in PBS-T(0.1%)
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solution to remove unbound material. After this washing step, the slides were blocked 
in any of the blocking solutions (see 3.1.8) by incubation at RT for 90’. Excessive 
blocking solution was removed by washing the slides 3 x T in PBS and leaving the 
slides in fresh PBS until application of the probe solution.
3.2.4 Labelling of probes
Homo- or heterogenous protein solutions were prepared in 0.1 M sodium carbonate 
buffer pH 8.0. Cy3 and Cy5 powders were brought in solution, each in 0.1 M sodium 
carbonate pH 8.0. Protein and dye solutions were mixed together in order to obtain a 
final mix containing 0.2 - 2 mg.ml~^of protein and a final dye concentration of 100 - 300 
jj,M. This mix was allowed to react in dark for 45’ at RT, and was quenched by addition 
of a tenth volume of 1 M Tris pH 8.0 (500 fold molar excess of quencher). The mix was 
brought to a volume of 0.5 ml with PBS, loaded into a microconcentrator spin column 
(Amicon Microcon 10) with a 10 kDa MWC and the volume was reduced to -  10 1^ by 
centrifugation (-20’, 15000 rpm in an Eppendorf bench centrifuge).
The dye was blocked with the addition of 25 /2I of a 3% skimmed milk solution in PBS 
(60’ at RT) and the volume was brought up to 0.5 ml with PBS. The blocked sample 
was loaded into a fresh Microcon 10 cartridge and concentrated to 10 ^1. The sample 
was brought up to 25 1^ with PBS and filtered by centrifugation in a 0.45 /im spin filter 
(Millipore) at 2000 rpm in an Eppendorf bench centrifuge. After filtration, the sample 
was ready for hybridization.
3.2.5 Hybridization
The washed slides were removed from the PBS bath and the excess liquid was shaken 
off. Without allowing the array to dry, we applied 25 /.J of the dye labeled protein 
solution to the surface of the array. The slide was then covered with a coverslip to 
ensure uniformity of the probe solution and to minimize evaporation. Covered slides 
were stored in a humid chamber at RT for 60’ (or ON at 4°C). After this incubation, the
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coverslip and the protein solution were removed by gently dipping the slides in PBS, 
and the slides were washed 2 x 5’ in PBS-T (0.1%), 2 X 5’ in PBS and 2’ x 5’ in ddH20 
at RT. The slides were then spun dry and scanned using a microarray laser scanner.
3.3 Methods - HybriChips
Immunizations, cell culture and ELIS As were performed by Alan Sawyer, Pieranna 
Chiarella and Heike Wilhelm of the Monoclonal Antibodies Core Facility at the EMBL.
All immunizations were performed using 20 ^g of antigen for the primary injection, 
followed by boosts of 10 /xg each.
3.3.1 Immunization protocois
3.3.1.1 Alum protocol Antigens were mixed 1:1 with Alum adjuvant in combination 
with the oligonucleotide CpGDNA (10 nmols/mouse). Samples were mixed at RT for 
30 minutes and then injected half intraperitoneal and half subcutaneous (2 subcut). 
Last boost (pre-fusion boost) has to be done at least 3 weeks after the previous boost. 
Animals were boosted every three weeks and bled 10 days after the boost. Blood 
was collected in separator tubes and spun down at 3000 rpm for 4 minutes in order to 
isolate the serum. Serum was then tested against the target antigen by ELISA in serial 
dilutions (1:500, 1:2500, 1:10000 and 1:50000)
3.3.1.2 RIbi Injection protocoi Mice were injected every 3 weeks with the antigen 
mixed 1:1 with Ribi adjuvant. Half of the sample was injected subcutaneous and half 
intraperitoneal. 10 days after the boost, blood was collected in separator tubes and 
spun down at 3000 rpm for 4 minutes in order to isolate the blood serum. Serum was 
then tested against the antigen by ELISA in serial dilutions (1:500, 1:2500, 1:10000 
and 1:50000)
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3.3.1.3 Details of Ribi adjuvant This adjuvant (MPL+TDM) is a stable oil-in-water 
emulsion which can be used as an alternative to the classical Freund’s water-in-oil 
emulsion. It has been proven to be a powerful immunostimulant (Thompson et al., 
1998; Ryil et al., 2001). MPL: Monophosphoryl LipidA (highly refined non-toxic LipidA 
isolated from re-mutants of Salmonella minnesota) TDM: synthetic Trehalose Dicoryno- 
mycolate (analogous of trehalose dymisolate from the cord factor of Mycobacterium 
tuberculosis).
3.3.1.4 Immuneasy injection protocoi Antigens were mixed with a certain amount 
of Immuneasy adjuvant (Qiagen) according to the manufacturer’s instruction, mixed at 
RT for 5-10 minutes and then injected with a 2 weeks interval. Half of the sample was 
injected subcutaneous and half intramuscular. The animal serum was collected 10 
days after the boost and tested against the antigen by ELISA in serial dilutions (1:500, 
1:2500,1:10000 and 1:50000). The last boost (pre-fusion boost) has to be done two to 
eight weeks after the previous injection. The short protocol we used in the 80 Antigens 
trial consisted of 1 injection and 1 boost which coincides with the pre-fusion boost.
3.3.1.5 Details of immuneasy adjuvant and importance of using CpGDNA Im­
muneasy Mouse adjuvant contains CpGDNA, short oligonucleotides that contain un- 
methylated cytosine-guanine dinucleotides within a certain base context. The mam­
malian immune system has evolved to recognize these sequences, which are found 
naturally in bacterial DNA, as a sign of infection. Exposure to CpGDNA results in very 
rapid and strong immune activation and, when applied with an antigen, CpGDNA pro­
duces high titers of antigen specific antibodies. Since Immuneasy mouse adjuvant 
induces high antibody titers in a short period of time, boosting can be performed ear­
lier than with other adjuvants. The amount of CpGDNA used in the preparation of the 
samples is unknown.
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3.3.2 Fusion protocols
All steps were performed under sterile or aseptic conditions in a laminar flow hood. 
Spleens were rendered into single-cell suspensions by mechanical disruption between 
two frosted-end glass microscope slides. The suspensions were filtered into 50ml bar- 
coded conical-bottomed tubes (BD Falcon) through 70 m nylon cell strainers (BD Fal­
con) and transferred to the robotic system. Separately, SP2 myeloma fusion partners 
(ATCC) were cultured for five days prior to fusion in HM20 (DMEM, 20% Defined fetal 
bovine serum (Flyclone Defined), 10mM L-Glutamine, 50 M Gentamicin) and on the 
day of the fusion were transferred to HM20/HCF/2xOPI (HM20 containing 10% Hy­
bridoma Cloning Factor (Origen) and 2%0PI cloning supplement (Sigma)) for at least 
one hour at 37^C in a 5% CO2 incubator. The tubes were centrifuged at 100 g for 10' at 
RT and the cells were resuspended in 5 ml Red Cell Lysis Buffer (Sigma) for 9 minutes 
at RT. HM20 was added to reach a final volume 50ml and again centrifuged for 10 min 
at RT with no brake. The supernatant solutions were aspirated to waste and the cells 
resuspended in DMEM preheated to 37°C. Cells were washed twice more by steps of 
centrifugation and resuspension. 50 ij,\ of cell suspension were robotically pipetted to
1.5 ml microcentrifuge tubes and counted using a haemocytometer counting chamber. 
Simultaneously the SP2 cells were washed three times in a similar fashion and a sim­
ilar aliquot (50 /xl) was removed to a 1.5 ml tube for haemocytometric counting. SP2 
myelomas and spleen cells were mixed at a ratio of 1:5 (SP2:Spleen) and again cen­
trifuged at 100 g for 10 min with no brake. The supernatants were entirely aspirated to 
waste and Polyethyleneglycol 1500 in 50% HEPES (PEG: Roche Molecular Biochem­
icals) pre-heated to 37°C was robotically pipetted smoothly and progressively over 1 
min with rotation at 450 rpm on a Te-shake shaker (Tecan AG) to ensure even mixing. 
The cell/PEG mixtures were incubated for 1 min at 37°C with gentle agitation. 1 ml 
of DMEM was similarly added over 1 min at 37°C with similar agitation. The mixture 
was incubated for 1 min at 37°C with gentle agitation. A further 1 ml of DMEM was 
robotically added over 1 min at 37°C with gentle agitation and incubated similarly for
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a further minute. 7 ml of HM20 were robotically added over 3 min at 37°C with gentle 
agitation. The tubes were then spun at 90 g for 5’ with brake. The supernatant was as­
pirated to waste and the pellet manually resuspended in 20 ml of HM20/HCF/OPI/AH 
(FIM20/HCF/OPI plus 10% Azaserine Hypoxanthine (Sigma)). The conical tubes were 
again placed on the robot workdeck and the post-fusion cell slurry was aspirated by 
each of the 8 wide-bore pipette tips of the liquid handling arm of the robot. 200 fi\ of 
the cell slurry was then pipetted into each well of a 96-well deep well plate (Greiner 
Masterblock), The deep-well plate was then robotically transferred to a TeMo 96-well 
pipetting robot integrated onto the Genesis work-deck and used as a source plate 
to plate out into the 20 sterile 96-well tissue culture plates. The post-fusion mixture 
was then robotically plated out into 20 X 96-well sterile plates (Nunc) sourced from a 
carousel attached and integrated to the robot at 100 /xl/well and robotically transferred 
to an integrated 37°G incubator with 10% CO2 through the integrated airlock.
3.3.3 Cell culture
On the third day after the fusion, cells were robotically transported from the incubator 
to the work deck and a further 100 ij,\ HM20/H OF/OP I/AH was robotically added. On 
day 7 the plates were once again similarly transported from incubator to work deck and 
200 ^I/well of the culture supernatants was aspirated to waste and replaced with 150 /xl 
fresh HM20/HCF. On day 11 the plates were again robotically transported to the work 
deck and 40 /xl of supernatant was collected from each well (Temo head: Tecan Inc.) 
and transferred to 384-well plates (Greiner) supplied to the workdeck by a carousel 
plate stacker (Tecan Inc).
3.3.4 Enzyme-Linked Immunoadsorbent Assay (ELISA)
96 well plates were coated with 4 ^g/ml of antigen and incubated overnight at 4°C. 
Plates were washed in PBS-T and blocked with 3% BSA in PBS for 1 hour at RT. 
50 jj,\ of hybridoma supernatant was added to each well and incubated for 1 hour at 
RT. After 4 washes in PBS-T, plates were incubated for 1 hour at RT with alkaline
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phosphatase conjugated anti-mouse secondary antibody, diluted 1:5000 in PBS. Plates 
were washed in PBST and incubated with p-nitrophenyl phosphate for 10-15 min at 
RT. Reaction was stopped by adding 50 1^ of 2 M NaOH and the optical density was 
spectrophotometriclly determined at 405 nm.
3.3.5 HybriChip preparation
Aminosilane modified microscope slides (EMBL, Heidelberg) were homogeneously 
coated with 5 L^^g of antigen in 50 fi\ PBS using a 24x60 mm coverslip. Slides were 
incubated in a humid chamber at RT for 60 minutes, the coverslip removed and sub­
jected to three five-minute washes in PBS. Slides were blocked in a 3% BSA solution 
in PBS for 60 minutes at RT. After five, 5 minute washes in PBS, the slides were dried 
by centrifugation.
Hybridoma supernatants were spotted onto the slides using a MicroGrid II 600 arrayer 
(ApogentDiscoveries, UK), using 32 MicroSpot 2500 pins in an 8x4 array (ApogentDis- 
coveries, UK). Humidity and temperature are maintained at 40% and 24°C respectively. 
Slides were then left to incubate in the arrayer for a further 60 minutes. The microar­
rays were washed five times 5 min in PBS and incubated with 40 1^ of a mix of Cy3- 
conjugated goat anti-mouse IgG and Cy5-conjugated goat anti-mouse IgM (Jackson 
Immunoresearch, West Grove, PA) both diluted 1:1000 in 3% BSA-10% Glycerol (60 
minutes, RT, humid chamber). Microarrays were then washed twice for 5 min in PBS-T, 
twice 5 min in PBS and finally rinsed in ddH20. Microarrays were dried by centrifuga­
tion and scanned in an LS400 Scanner (Tecan, Austria), using 633 and 543 nm lasers 
respectively for Cy5 and Gy3 excitation and 670 and 590 nm emission filters.
3.3.6 HybriChip analysis
Image analysis was performed using the GenePix Pro 4.1 software package (Axon 
Instruments, USA). Spots for which the diameter is not included in a fork of 80 -15 0  
/xm or of bad quality (scratches, heavy background, dust, etc) were ignored. For each
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remaining sample, we retrieved the median of the medians of the intensities of each 
group of replicates (MR). Each value was then normalised against the median value 
of all the MR of the chip [MR/(median of total MR)]. Samples showing a normalised 
value inferior to 2 were considered negative. Values between 2 and 20 were consid­
ered putative positives, while all samples having a normalised value equal or over 20 
were considered positives. Data analysis was performed using a proprietary software 
application, HyCAT (Hybridoma Chip Analysis Tool).
3.3.7 Immunofluorescence
Coverslip preparation 12 mm glass coverslips were soaked in a 60:40 (vokvol) 
Ethanol-HCI solution for 60’ and extensively washed with ddH^O. Clean coverslips 
were then incubated in a water solution containing 0.1 mg.mh^ poly-L-lysine (70 kDa 
or higher) for at least 2 hours. After washing and drying, the coverslips were sterilised 
under UV light.
Treatment of cells The prepared coverslips were overlayed with 10° XL117 cells 
{Xenopus laevis). The cells were allowed to recover and attach to the coverslips 
overnight. Fixation of the cells was done using two methods:
1. Paraformaldehyde: Coverslips were placed into a 12 well plate and overlayed 
with 1 ml of filtered 4% PFA, 0.1% GA, 0.5% TritonXlOO in 1x BRB80, for 15 to 
20 minutes. The fixation solution was gently removed by aspiration and replaced 
with a PBS solution containing 1 mg.mh^ NaBH^ . Samples were left in this 
solution for 10 minutes.
2. Methanol: Coverslips were dipped into a methanol container at -20°C for 10’.
Immunostaining After fixation of the cells, the coverslips were allowed to equilibrate 
in TPBS. The samples were incubated for 20 minutes with a mixture of undiluted hy­
bridoma supernatants and an anti-aTubulin polyclonal antibody (1:200 in TPBS) and
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washed twice with TPBS. The cells were subsequently incubated with a mixture of anti­
mouse IgG and anti-rabbit IgG, respectively coupled to Alexa468 and Alexa588 fluo- 
rophores at 1:1000 dilution in TPBS. After washing with TPBS, the DNA was stained 
with 5 /Lig.mh^ Hoechst dye in TPBS and the coverslips were mounted in Mowiol.
Image acquisition and anaiysis Samples analysis was carried out on a Zeiss Axio- 
scope fluorescence microscope. Image acquisitions were carried out using Image Sis 
F-View digital camera controlled by Analysis software.
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4 Results
4.1 Establishment of a protein chip platform
When the project was initiated, only two reports of protein microarrays on glass sup­
ports had been published (MacBeath and Schreiber, 2000; Haab et al., 2001). There­
fore, because of the novelty of this technology, all aspects regarding the production and 
generation of protein microarrays had to be established ab initio, starting from EMBL’s 
extensive knowledge and experience in DNA microarrays and from the mentioned pa­
pers from Macbeath and Haab.
4.1.1 Determination of a functional surface chemistry for protein microarrays
The first aspect that had to be investigated was the determination of the appropriate 
surface chemistry (substrate), to be used for an efficient attachment of proteins to a 
glass slide. In Haab’s report, 115 proteins were successfully attached and detected 
onto poly-L-lysine coated microscope slides. It seemed then, that this substrate would 
allow for a specific immobilization of an extensive range of proteins, thus being a ’’pro­
teome wide” substrate. We decided to test this solution and try to reproduce some of 
the published observations. Two different substrates were tested in parallel: poly-L- 
lysine and a proprietary modified aminosilane chemistry, which is currently used in our 
laboratory for the production of DNA microarrays (EMBL surface chemistry). These 
very first experiments were carried using the well characterized IgG-ProteinG (Bjorck 
and Kronvall, 1984) and IgG-Protein A interactions (Forsgren and Sjoquist, 1969).
Human IgG was manually spotted onto both chemically modified slides. The microar­
rays were hybridised with a solution containing Gy3 labelled Protein A and Cy5 labelled 
protein G. The slides were scanned using both 635 and 533 nm lasers (Gy5 and Gy3 
respectively). Figure 3 shows that while no signal was obtained by the poly-L-lysine
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(left image), both Protein A and Protein G were able to bind to the immobilized hIgG 
on the EMBL chemistry slides. It appeared that the spotted hIgG was not retained 
onto the poly-L-lysine slide, thus was washed off during the array processing. From 
this observation, it was decided to base all further experiments on the EMBL surface 
chemistry.
B
Figure 3. Surface chemistry analysis: poly-L-lysine vs EMBL chemistry
A - Poly-L-lysine coated slide: no signals can be detected after hybridisation and scanning 
of the slide
B - Aminosilane coated slide: processed exactly as the poly-L-lysine, this chemistry ap­
pears to allow for the attachement and detection of proteins on the glass surface
4.1.2 Can immobilized proteins be detected by specific interaction partners in 
a microarray experiment?
Having established that the EMBL surface chemistry allowed for the attachment of 
hIgG, we wanted test the detection specificity of the arrays. We prepared a chip con­
taining a set of different antibodies specific for proteins or expression tags and where 
Protein A and Protein G were used as negative controls. The layout of this manually 
spotted chip can be seen in Table 2.
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His His GST GST Ik B/3 kB/3 Ik B q l«B a Fractalkine Fractalkine
His His GST GST l«B/3 Ik B/3 l/cBa l/cBa Fractalkine Fractalkine
ProtG ProtG FLAG FLAG ProtA ProtA l«B a-H 4 lAcBa-H4 Mip1a Mip1a
ProtG ProtG FLAG FLAG ProtA ProtA lKBa-H4 l/cBa-H4 Mip1a M ip ta
Table 2. Layout of the antibody microarray
All samples were spotted manually, where each spot contained 100 ng of sample. All im­
mobilised samples are antibodies raised against the stated protein or expression tag. Pro­
tein G (ProtG) and Protein A (ProtA) are the full length proteins, and are used as negative 
controls. Ik.Bo!-H4 is an antibody specific for the N-terminus of IkBq
In order to determine the specificity of our system, we hybridised this chip using a so­
lution containing two sets of differentially labeled antigens (Cy3 and Cy5). The first 
set, labeled with Cy5, contained proteins that included an expression tag (His, GST, 
FLAG) or a post-translational modification (biotinylation). The second set (Cy3) con­
tained some of these same proteins, expressed without tags. Table 3 shows the exact 
contents of these mixtures.
Protein contents of the 
hybridisation solution Labelling Reagent
Fractalkine
Ik Bm
Ik B/:!
M ip ta
Cy3
GST-lKBa( 1-54) CyS
GST-MAP3K2
GST-MAP3K3
FLAG-Mipt a
FLAG-Fractalkine
B io tin-kBo
His-lAcBa
Table 3. Hybridisation solution for the antibody microarray
Cy3 labelled proteins and Cy5 labelled tagged proteins were pooled into a single hybridis­
ation solution. Each set contained a total of 20 ng of sample
Figure 4 shows a graphical description of the expected results (table) together with the 
obtained results (image). From the scanned image, we can appreciate that the negative 
controls did not show any signal. This was the expected result since Protein A and
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protein G could only bind to IgG molecules, which were not present in the hybridisation 
solution. We could also observe a positive detection of the anti-FLAG, anti-kBa-H4, 
\kB(3 and anti-GST antibodies. However, the anti-FLAG antibody also showed to have 
some degree of unspecific binding, since it appears that Cy3 labelled sample was able 
to interact with that antibody. There is no signal for the anti-Fractalkine, anti-Mip1a and 
anti-kBa antibodies, while the signals are very low for the anti-His sample. Considering 
that these antibodies were never tested on a microarray format, we could not speculate 
any further on these results, other than saying that there is some level of specificity in 
detection.
His His GST GST Ik.B /Ï Ik B/3 I^Ba l/cBrc Fractalkine Fractalkine
His His GST GST \k B.3 l«B/3 Ik B cv In B cv Fractalkine Fractalkine
ProtG ProtG FLAG FLAG ProtA ProtA lK;Bf>-H4 lKBf»-H4 Mip1« M ip ta
ProtG ProtG FLAG FLAG ProtA ProtA lK.Ba-H4 lKBa-H4 M ip ta M ip ta
Figure 4. Manually spotted antibody microarray
Pictorial result of the antibody microarray. The top table gives an overview of the expected 
results
Following this experiment, a "reverse" microarray was generated. The antigens previ­
ously contained in the hybridisation solution were spotted onto an EMBL slide (Table 
4), and their specific antibodies were used for hybridisation (Table 5). Differently from 
the antibody chip, Protein A and Protein G were here used as positive controls. A 
phage protein, T4E7, was used as negative control.
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MAP3K2-GST Frac-FLAG kBa-His GST-kBa-NT T4E7 Mipl a Frac
MAP3K2-GST Frac-FLAG kBa-his GSTkBa-NT T4E7 Miplo; Frac
MAP3K3-GST Protein A Mipla-FLAG kBa-Biotin T4E7 kB a \k BP
MAP3K3-GST Protein G Mipl q-FLAG kBa-Biotin T4E7 kB a kB/3
Table 4. Layout of the antigen microarray
All samples were spotted manually, where each spot contained 100 ng of sample. Protein 
G (ProtG) and Protein A (ProtA) are used as negative controls (binding of IgG molecules). 
T4E7 is a X-resolvase from T4 phages, here used as a negative control. All samples were 
hand-spotted in 0.2 /j,\ drops containing 100 ng of sample
Antibody contents of the 
hybridisation soiution Antibody type Labelling Reagent
FLAG Monoclonal CyS
GST Monoclonal
His Monoclonal
kBc%-H4 Monoclonal Cy5
k B a Polyclonal
\k B 0 Polyclonal
Fractalkine Polyclonal
Mip1a Polyclonal
Table 5. Hybridisation solution for the antigen microarray
Cy3 labelled antibodies and Cy5 labelled antibodip-'ajVvere pooled into a single hybridisa­
tion solution. Each set contained a total of 20 ng of sample
Figure 5 shows a graphical description of the expected results (table) together with the 
obtained results (image). Both positive controls, Protein A and Protein G had been 
detected by the IgG molecules contained in the hybridisation solution. The negative 
control T4E7 seemed to generate a positive signal on one of its locations. However, 
this could have been caused by the background signal present on that area of the 
slide. A clear positive signal from the anti GST, Fractalkine, and kB a  antibodies was 
also observed. Of the immobilized samples that should have shown a double recogni­
tion (Fractalkine-FLAG, Mipla-FLAG, kBa-His and GST-kBa-NT), only GST-kBo^-NT 
shows the expected signal (yellow). As for the negative controls, the "top" area of this 
chip presented some background on the Cy3 channel, therefore we can not postulate
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whether the orange signal detected for the two upper spots for FLAG-Fractalkine and 
H is-kBfi were due to the correct binding of the anti-FLAG and anti-His antibodies. 
Furthermore, we can see that the anti-Mip1a antibody did not recognise its antigen. A 
very weak signal is seen from the un-tagged form of kBa, while no signal is seen for 
its biotinylated form.
We could conclude that these two experiments showed that proteins immobilized onto 
an aminosilane coated glass slide could be specifically detected by their interaction 
partners. However, some of the samples could not be detected and a little cross­
reactivity was detected. This could have been caused by the unprecise spotting proce­
dure and/or by the instability of certain proteins under these experimental conditions.
MAP3K2-GST T4E7 Mipl a Frac
MAP3K2-GST T4E7 Mipl a Frac
MAP3K3-GST kBm-Biotin T4E7 IkBo: IkB/3
MAP3K3-GST kBcv-Biotin T4E7 IkBq IkB/3
Figure 5. Manually spotted antigen microarray
Pictorial result of the antibody microarray. The top table gives an overview of the expected 
results
4.1.3 Upscaling of the system
All initial experiments were performed by manually spotting the proteins onto the glass 
slides and, as mentioned, this technique does not allow for a precise deposition of the 
sample. It was decided to reproduce the previous experiments using a robotic spotter. 
Other than having qualitative advantages, the use of such a robot would allow us to
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create titered arrays where different conditions, such as sample concentration and vol­
ume deposited on each spot, could be tested simultaneously. It is necessary to stress 
how the spotting hardware and protocols play a major role for the quality of the results 
to be expected. Using low quality spotting pins and non-optimal climatic conditions 
(air humidity < 36% or >50%; temperature < 30°C) could lead to loss of sample func­
tionality. These initial experiments were carried on an old GMS417 spotter, mounted 
with a pin-and-ring printing head. Depending on pin straightness, fluid viscosity and cli­
matic conditions, more or less sample will be uploaded/printed thus leading to potential 
losses or increases of spot intensities.
A new antigen chip was produced, where the same antigens used for the prior exper­
iments would be immobilized onto the slide at different concentrations (0.1 and 0.05 
mg.ml~^). Additionally, each sample was spotted in three distinct sets, where the pin 
dispensing the solution would hit the same location 1, 3 and 5 times. The aim of this 
layout was to determine the optimal spotting conditions in terms of sample amounts. 
Table 6 illustrates the layout of this chip setup.
1— 1—W  CD
( D O  Q)S Û  Î  I  1
I I I  t  I I I
1 § g
^  ^  % -  1 î  é  f  § g i  è  i
1 hit 1 hit
Shits Shits 0.1 mg/ml
Shits Shits
1 hit 1 hit
3 hits 3 hits 0.05 mg/ml
5 hits 5 hits
Table 6. Layout of the robotically spotted antigen microarray
Samples were spotted at decreasing concentrations (0.1 and 0.05 mg.mkl and with in­
creasing volumes (1x 3x 5x the normal spot volume onto each spot)
The chip was hybridised with 40 /ig of differentially labelled antibodies (Cy3: anti-GST, 
anti-p53, anti-Fractalkine, anti-kBa-H4; Gy5: anti-kBa, anti-HisTag, anti-Mipla, anti- 
kB/?, anti-FLAG). Similarly, we produced an antibody array, where the antibodies were
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spotted at different concentrations (0.5, 0.25, 0.1, 0.05 and 0.01 mg.mh^) and number 
of hits (1, 3 and 5) (Table 7). The chip was hybridized with 40 1^ of a solution containing 
labelled tagged and non-tagged antigens (Cy3 and Cy5 respectively). Furthermore, 
Protein G and Protein A were also added to the Cy3 and Cy5 mixtures, as controls for 
the immobilized hIgG and ant-Protein A antibody.
Figure 6 shows the scanned imaged of the antigen microarray. As expected, both 
Protein A and Protein G did detect and bind the IgG antibodies. The results for the de­
tection of the immobilized antigens showed a good overall specificity. However, some 
expected interaction were only detected under precise spotting conditions, such as the 
GST-kBa-NT interaction with the anti-GST (or anti-kBa-NT) antibody which was only 
seen when more than 0.25 /ig of antigen was immobilized onto the slide (3 x 0.1 and 
5 X 0.05 mg.mh^). On the other hand, some specific interactions were seen when 
the amounts of antigen were superior to 0.5 ^g (M ipla and kBa). Some of the pre­
dicted interactions were however not detected. For example, kB a  and His-kBashould 
have been detected by antibodies present in both labelled solutions, thus generating 
a yellow signal. However, we can only see a red signal being generated. This could 
be caused by an improper presentation of the immobilised eptiope for the monoclonal 
anti-kBa-H4 anitbody (Cy3 labelled). Alternatively, that particular monoclonal might 
not be compatible with such an assay format. The first cause can be used as an expla­
nation for the lack of signal generated from the anti-FLAG antibody, since this particular 
reagent failed to generate results in the previous "hand-spotted" antigen microarrays. 
When immobilised onto the array (Figure 4 and 7), this antibody seems to be able to 
detect FLAG containing proteins, suggesting that the problem is arising from the spot­
ted antigens. Finally, as previously mentionned, some of the missing signals might be 
caused by non-optimal spotting conditions, thus unavailability of immobilised samples.
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Figure 6. GMS spotted antigen microarray
Pictorial result of the antigen microarray. The top table gives an overview of the expected 
results
Figure 7, shows the scanned imaged of the antibody microarray. The immobilized hIgG 
showed a positive binding to both Protein A and Protein G (yellow signal) and the anti- 
Protein A antibody showed a specific binding to Protein A only (red signal). As for 
the antigen microarray, a good correlation with the expected results (Table in Figure 
7) could be observed. Furthermore, we could appreciate the effect of the different 
spotting conditions for each immobilized antibody. Several of the samples can only be
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detected after their amounts on the slide are higher than specific thresholds, which are 
different from sample to sample. However, like for the previous experiment, some of 
the expected dual-binding signals were not detected. In this case, the most plausible 
cause for this lack of signal could be the labelling of the antigens. The molecules 
used to label the proteins could be interfering with the epitopes recognised by the 
immobilised antibodies, thus dramatically lowering the affinity of the antigen-antibody 
recognition or, most probably, inhibiting such interactions.
We could then conclude that both antigens and antibodies could be specifically de­
tected after immobilization and drying on a chemically modified glass surface. How­
ever, it appeared that spotting concentration plays a major role, especially for antibod­
ies. Antibodies should also be tested for microarray compatibility before usage. As 
previously discussed, some of the tested samples did not produce the expected sig­
nals and this could be caused by problems in epitope presentation, compatibility with 
this assay format or, possibly, by the blocking of binding sites by fluorophore molecules.
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Block 1 a Blocki b Block 1 c Block 2a Block 2b Block 2c Hits
0.5 0.1 0.01 0.5 0.1 0.01 1
3
5
0.25 0.05 0.25 0.05 1
3
5
Table 7. GMS spotted antibody chip layout
Samples were spotted at decreasing concentrations (from 0.5 to 0.01 mg.ml) and with in­
creasing volumes (1 - 5 hits per spot). Block 1 contains anti l« B a -H 4 , FLAG, Fractalkine, 
hIgG and Mipla antibodies and Block 2 contains \kB(3, k B a ,  GST, Protein A and HisTag 
antibodies.
m Wo
ÇIQ_
t(0 X
Figure 7. GMS spotted antibody microarray
Pictorial result of the antibody microarray. The top table gives an overview of the expected 
results. Antibodies were spotted at different conditions (see previous table) These differ­
ent areas are separated by blue delimiters.
4.1.4 Do proteins maintain a correct folding after Immobilization?
Having determined the basic protocols for the immobilization and detection of proteins 
onto glass slides, we needed to better assess the stability of proteins after their attach-
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ment. All the previous experiments were done using antigen/antibody pairs. Antibodies 
are very stable proteins and can recognise linear epitopes resulting from unfolded pro­
teins. This characteristic of antibodies could not allow us to make conclusions about 
the stability of the attached proteins.
To answer this question we used a combination of two proteins, TAP and p15. TAP 
is a mRNA transporting protein, which requires dimerization with p15 in order to be 
functional (Fribourg et al., 2001). We obtained purified TAP and p i 5, together with a 
mutant ATAP which lacked the p i 5 binding domain (Izaurralde, EMBL). All three pro­
teins were spotted, together with Protein G (positive control). The microarray was then 
hybridised with a mixture of Gy3-p15, Gy5-TAP and Gy5-hlgG. If the spotted proteins 
are structurally stable, we should obtain a specific green signal on the immobilized TAP, 
a red signal for p15 and Protein G and no signal for the ATAP protein (no binding to 
p15). Figure 8  shows the result of this experiment.
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Figure 8. Proteln-protein interaction study: TAP/p15 binding analysis
TAP (green box), p15 (yellow box) and ATAP (blue box) were immobilised onto the slide, 
together with Protein G (positive control, red box). Pre-labelled TAP and IgG bind to their 
partners, pi 5 and Protein G. Pre-labelled pi 5 binds to the immobilised TAP but not to 
ATAP. This results shows that proteins can maintain a correct folding after immobilisation 
onto a glass slide
TAP and p i 5 are able to detect and bind their specific partners, while there is no sig­
nal (detection) from the immobilized ATAP. This showed that the results were obtained 
from a correct folding of the immobilized samples. If the immobilized proteins would 
have lost their structural features, these TAP/p15 interactions would not have been 
possible. We could therefore conclude that proteins were structurally stable once im­
mobilized and dried onto a glass surface.
With these experiments, we had shown that we were able to produce functional protein 
microarrays. We were able to specifically detect antibody/antigen, antigen/antibody 
and protein/protein interactions in a solid phase experiment. Having determined the
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feasibility of protein microarrays, we could start designing and executing experiments 
based on this technology.
F. De Masi 9606101
____________________________________________________________ 4 RESULTS
4.2 HybriChips
4.2.1 Design of a monoclonal antibodies screening platform
After having considered several screening strategies (see Section 6.2), we decided to 
design a novel method, in which a library of hybridoma supernatants (HSs) would be 
spotted onto a layer of purified antigen, homogeneously attached onto a chemically 
modified slide (Figure 9 A). These arrayed spotted HSs would be hybridised with a 
mixture containing Cy3 labelled anti-mouse IgG and Cy5 labelled anti-mouse IgM (Fig­
ure 9 B). This system would allow for the detection of those hybridomas expressing the 
specific anti-antigen monoclonal antibodies, together with a direct isotyping of these 
detected antibodies (Figure 9 0).
■ k
Figure 9. Hybridoma screening strategy
A - A chemically modified slide is homogeneously coated with purified antigen. Hyr- 
bidoma supernatants are succesively spotted onto this antigen layer.
B - The microarray containing the spotted hybridoma supernatants is hybridised with a 
solution containing Cy3 labelled anti-mouse IgG and Cy5 labelled anti-mouse IgM.
C - Isotype specific signals (green: IgG, red: IgM) are detected from the spots presenting 
hybridoma supernatants containing monoclonal antibodies specific for the coated antigen
4.2.2 Coating of slide with antigen
The first step for validating our approach, was to test whether the coating of a slide 
with a homogeneous layer of antigen could be done. 20 fi\ of PBS containing 3 .2  //g 
of Cy5 pre-labelled kBa, were dispensed onto an aminosilane modified glass slide. 
After a 60’ incubation at RT in a humid chamber, the slide was dried and scanned 
(Figure 10 A). The slide was subsequently blocked in a 3% Skimmed Milk solution
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in PBS-T, washed 2 x 5’ in PBS-T and scanned again (Figure 10 B). Following this 
biocking step, the slide was extensively washed and scanned for a final time (Figure 
10 C). The three resulting images were analysed in order to determine the amounts of 
antigen lost and retained onto the slide surface after blocking and washing. From the 
data analysis (Figure 11), we can observe that even though a large amount of material 
is lost following the washing and biocking steps, there is a good retention of material 
onto the slide. However, it is not possible to absolutely confirm this observation since, 
because of the various scanning procedures, the fluorophore used for this experiment 
might have been subjected to intensive laser-induced photobieaching, thus reducing 
the signal intensity of the coated surface. Another important observation from this 
experiment is the apparent lack of coating uniformity. It is quite evident that there 
is more signal emitted from the central area of the slide, compared to the peripheral 
regions. This factor might result in a increased background signal and, possibly, will 
lower the selection stringency in that central area. This is due by the higher number 
of antigen molecules present in the central area, which allows for a higher number 
of epitopes to be presented to the screened antibodies, thus lowering the required 
affinity for proper binding to occur. It could be also possible that the increased signal 
in the central part of the slide is due by the free fluorophore molecules present in 
the antigen solution. Considering a normal tendency for peripheral evaporation, an 
increasing concentration of soluble fluorophores should be found in the liquid phase 
present in the less exposed area of the slide.
However, it appears quite clearly that it is indeed possible to coat a microarray slide 
with a layer of purified antigen. This allowed us to proceed with the establishment of 
this novel hybridoma screening platform.
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Figure 10. Slide coating with homogeneous layer of antigen
A) Initial coating of a slide: an aminosilane modified slide was overlayed with a homoge­
neous and Cy5 labelled kBa solution, incubated for 60’, dried and scanned
B) Determination of the amounts of antigen available to the hybridoma supernatants prior 
to spotting: the slide was washed in PBS-T, blocked with a 3% skimmed milked solution in 
PBS, dried and scanned
C) Amounts of antigen retained after the full processing of the microarray: after a 60’ 
wash in PBS-T, the slide was scanned for a final time
Coating area was delimited by a hydrophobic barrier, applied with a hydrophobic marker 
(PapPen)
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Figure 11. Chip coating experiment: data analysis
Each chip was analysed using the GenePix 3.0 software. For each slide, we retrieved the 
median of intensities for each channel. The histograms show the data relative to each 
step of the experiment. The loss of signal after the washing steps is quite evident on the 
Cy5 channel (F635), while there is no major change for the Gy3 channel (F532).
Empty slide: no antigen coating; Coating: antigen dispensed, no wash; 1st Wash: chip 
analysed after blocking and 2x5’ min wash procedure; 2nd Wash: chip washed 3x10’ in 
PBS-T, 3x10’ in PBS, 1x10’ in ddH20.
4.2.3 Detection of Coated Protein by Antibodies
Having determined that we could uniformly coat a slide with an antigen, the next step 
was to test whether it would be possible to detect monoclonal antibodies recognising 
and binding to the antigen layer.
We tested this approach using an antigen-antibody pair, which had been determined 
to be functional on a protein microarray experiment (see section 4.1.2). We coated a 
slide with 3.2 //g of kB a  as previously described, and blocked the chip with 3% Milk 
in PBS-T. After drying of the chips, a Cy5 labelled rabbit polyclonal antibody specific 
for the C terminus of kB a  (kBa-H4) was manually spotted onto the the coated slide.
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A mixture of Cy3 labelled antibodies^ was similarly spotted onto the same slide, to 
act as negative controls. Figure 12 A shows that both samples are clearly visible after 
spotting, with the red and green signal showing the anti-kBa antibody and the negative 
control mixture respectively. Figure 12 B shows that only the signal from the anti-kBa 
is detected after washing of the slide.
Figure 12. Detection of specific antibodies on an antigen coated slide
Cy5 labelled anti-kBa and Cy3 labelled monoclorai anti-GST, polyclonal antibodies anti- 
Miplaand anti-Fractalkine were spotted onto an t. -Bc. coated slide.
A - Scanned chip before washing: all spotted samples are visible 
B - Scanned chip after washing: only the Cy5 labelled anti-kBa antibody is detected. In 
order to avoid the appearance of false-negative results for the negative control spots, the 
scanning parameters were modified at run-time. The the scanning procedure was initi­
ated using the same parameters as of figure A (laser: 100%, PMT: 450V) and terminated 
with a PMT value of 900V. This resulted in a clearly visible increase of background for the 
second half of the chip
Having obtained a specific detection of the attached antigen to the slide (no negative 
controls were detected after processing of the slide), we had to address whether this 
observation could be reproduced using hybridoma supernatants (HS - unpurified anti­
body) and whether this could be done by using am automated spotter, thus detecting 
sub-picoliter quantities of antibody. The EMBLs Monoclonai Antibodies Core Facility 
(MAGF), with which this project was carried out, provided nine hybridoma lines secret-
 ^monoclonal anti-GST (mouse), polyclonal antibodies anti-M ip la  and anti-Fractalkine (goat)
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ing monoclonal antibodies raised against human TPX2 protein. We coated a glass 
slide with purified TPX2 (1 fig) and the nine HSs were spotted onto this slide. A set of 
negative controls, consisting of monoclonal antibodies against kB a  and p52 together 
with 20% FBS in DMEM (negative control for the culture medium) was spotted onto 
this TPX2 layer. Figure 13 shows that following hybridisation with a labeiled anti-mouse 
IgG antibody (all spotted antibodies were mouse IgGs), only the anti-TPX2 hybridoma 
supernatants were detected. No signal originated from the negative controls. This 
demonstrates that the system is able to specifically detect only those antibodies that 
were raised against the coated antigen.
20-1D7
9-90520-101
3-609  
20-107
4 -907  
4 -907  
9-905  3-6A8I kBa 
3-6AB
20-101
3 -609
19-16B8
Figure 13. Detection of characterised monoclonal antibodies on an antigen coated 
slide
Nine hybridoma supernatants raised against hTPX2  were spotted onto a TPX2 coated 
slide. Two mAbs specific for kBa and p52, together with DMEM, where used as nega­
tive controls. After incubation with the spotted antibodies, the slide was washed and hy­
bridised with a Cy3 labelled anti-mouse IgG secondary antibody (1 :1 0 0 0 , vohvol). There 
is a clear signal from all spoted anti-TPX2 monoclonals, while no signal is detected from 
the negative controls
4.2.4 Screening of Hybridoma Library (1 antigen)
We were then able to show that we could coat a slide with a homogeneous solution of 
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antigen and that we could spot and selectively detect monoclonal antibodies against 
that antigen. However, the latter experiment was carried out with previously charac­
terised hybridomas and known negative controls. We needed to test whether this sys­
tem could be used to specifically and quickly detect and select specific antibodies from 
a library containing thousands of uncharacterised hybridomas. While testing five differ­
ent immunization strategies, the MAC F generated a library of 9600 hybridomas raised 
against TPX2. This library was tested against a TPX2  coated slide, using the protocols 
established in the previously described experiment (section 4.2.3). The nine positive 
hybridomas used for the first test were spiked into this library in locations unknown to 
me (blind positive controls). To allow for a direct isotyping of the detected monoclonal 
antibodies, the spotted HSs were hybridised with a solution containing both Gy3 and 
Cy5 conjugated anti-mouse IgG and IgM antibodies. To obtain a solid set of data to 
perform statistical analysis on, the supernatants were spotted singly, onto three anti­
gen coated slides. This was necessary since it was not possible to spot in triplicate 
such a high amount of samples onto a single slide. 60 positive HSs, of which 45 IgG 
and 15 IgM, were selected form the analysed arrays (Figure 14). These selected HSs, 
together with randomly selected chip-negative samples, were tested by a conventional 
ELISA screen, in order to confirm their positive recognition of TPX2.
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Figure 14. Screening of 5 TPX2 fusions:by antigen coated microarrays
Hybridoma supernatants from five fusions generated from mice immunized against TPX2 
were spotted onto a TPX2 coated slide. The hybridoma supernatants were hybdridised 
with a mxture of Cy3 and Cy5 labelled anti-mouse IgG and IgM respectively.
Close-ups show magnified areas of the microarray were antibodes have been detected 
and directly isotyped (IgG: Green signal - IgM: Red signal). Blue arrows point at the hy- 
bridoma’s ID
The ELISA confirmed the positivity of the IgG and IgM monoclonal antibodies detected 
with the microarray screen and showed that all nine "blind" positive controls had been
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detected by the assay (Figure 15).
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Figure 15. ELISA screening of chip-identified hybridomas
IgG (plate 1 ) and IgM (plate 2) monoclonal antibodies detected by the chip analysis were 
tested by ELISA. Of the 45 sleeted IgGs, 9 were identified as being the "blind positive 
controls" spiked into the spotting plates and were used as positive controls for the ELISA. 
Bound areas in the ELISA plates represent positive (0+) and negative (C-) controls. 
Microarray image of a negative and four positive samples are also shown. "Average la" 
and "Ic" values are explained in Section 5.1.1
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4.2.5 Screening of library of antibodies raised against more antigens
We had demonstrated that we could use an antigen coated microarray based screen 
to analyse a extensive number of hybridomas in a fast and specific manner. However, 
since the goal of the project was to generate a high throughput method for the gener­
ation of monoclonal antibodies, a fundamentai point of this was the possibility of using 
multiplexing immunization protocols (several distinct antigens injected in a single ani­
mal) combined with a highiy selective screening method. We therefore needed to test 
whether our screening strategy could be used to detect and select specific samples 
from a library of hybridomas generated from a multiple antigen immunization. An ex­
periment was designed where a single mouse was immunized with two unrelated anti­
gens: Xenopus laevis 7 -Tubulin (C-terminal 15 amino acids - AATRPDYISWGTQDK) 
and the Ket94 domain of Drosophila megalonaster muscle protein Titin (Ket94, 23kDa 
protein). The resulting hybridoma library was spotted onto two separate chips, coated 
with Ket94 and 7 -Tub.
The analysis of the two microarrays was initially done visually and subsequently re­
peated using a method based on the mathematical analysis of the intensities of each 
spot. We used a simple algorithm, which determines the relative contribution of each 
spot to the total intensity if each chip. From the raw data, we calculate the average 
intensity of each set of spot replicates, and each value is divided by the total intensity 
of the chip. The resulting value represents the percentile contribution of that particular 
sample to the complete chip (Equation 1, in section 5.1.1).
From the visual analysis of the microarray results, 8  and 4 positive hybridomas for 
Ket94 and 7 -Tubulin were selected. These selected hybridomas were further tested 
by Western blot analysis (Figure 16) and by ELISA (not shown), where the selected 
samples were proven to be positive. This showed that we could discriminate between 
hybridomas secreting monoclonai antibodies against different antigens from a unique 
library. Interestingly, the same samples were selected when using the mathematical
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approach, which suggested that we could implement such a numerical approach for 
the selection of positive hybridomas.
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Figure 16. Western blot analysis of selected monoclonal antibodies
The selected monoclonal antibodies against Ket94 and ^Tubulin were tested by Western 
blot against a purified Ket94 antigen and the ^TubuHn's C-terminal 15 amino acids pep­
tide, expressed with a GST-tag. All samples were positive in this analysis
In parallel with the ELISA and the Western blQt^analyses, the anti-Ket94 antibodies 
were screened by immuno-gold labelling on a Drosophila muscle fibre (Kevin Leonard 
and Sigrun Brendel, EMBL) and the 7 -Tubulin hybridomas were screened by immunoflu­
orescence on Xenopus XL177 cells (with the help of Andrei Popov, EMBL). These tests 
showed that only one Ket94 sample was positive on the immuno-gold labelling exper­
iment, and two of the anti- 7 -Tubulin antibodies gave a signal in the IF test (methanol 
fixation). These experiments showed that some of the samples selected via the mi­
croarray screen were able to detect their antigen in experiments where it is not purified 
and in a un-denatured, cellular environment (Figure 17).
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Figure 17. Immuno-gold labelling and Immunofluorescence analyses using antibod­
ies identified by microarray screening
Selected monoclonal antibodies against Ket94 and ^Tub were tested by immuno-gold 
labelling (electron microscopy) and immunofluorescence.
The left panel shows a Drosophila’s muscle fibre, where the Ket94 regions of the large 
Titin proteins have been labelled by one of the selected mAb (red arrows).
The right panel presents a mitotic XL177 Xenopus cell, where the ^Tubulin containing 
centrosome has been lebelled and visualised by one of the selected mAbs (green arrow; 
red: atubulin; blue: DNA)
4.2.6 Upscaling of Immunization multiplexing: five antigens per fusion
However, using two antigens per animal could not ensure the throughput we were 
seeking for this project. W e needed to test this system with a higher number of anti- 
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gens in one singie animal. We decided to test the procedure using five antigens. The 
five proteins iisted in Table 8 were simultaneously injected in a single animal and, a f­
ter three boosts at 10 day intervals, the fusion was performed. The hybridomas cre­
ated were then screened by HybriChip and non-specific antibodies were eliminated by 
cross-referencing microarrays on different antigen chips. The positivity of all HybriChip 
selected IgG antibodies was confirmed by ELISA (Table 8). This experiment showed 
that it was possible to immunize one single animal with up to five antigens and that 
the screening of the resulting hybridoma library could be specifically done using our 
HybriChip platform.
Antigen Name
Total No. Positive 
Clones (HybriChip)
IgM secretors 
(HybriChip)
IgG secretors 
(HybriChip)
IgG secretors 
(ELISA)
Ago2 12 7 5 5
Mago JLY 17 8 9 9
KetB4 17 7 10 10
Tcnf2 29 9 20 20
Pig2Mut4 13 10 3 3
Table 8. Summary of results for a five antigen experiment.
Monoclonals were detected and obtained for all antigens tested. ELISA screens con­
firmed the positivity of all the IgG isotype monoclonals selected
4.2.7 Analysis of the correlation between HybriChip and ELISA results
At this point of the project, we had established that:
F. De Masi 70 9606101
4 RESULTS
• We could coat a chemically modified slide with a homogeneous layer of an anti­
gen
• We could specifically recognise the coated antigen with spotted antibodies
• We couid screen a library of hybridomas raised against multiple antigens using 
this approach
• By screening the hybridoma library using differentially labelled detection antibod­
ies, we could immediately determine the isotype of all positive antibodies
• All the HybriChip positive hybridomas were positive by ELISA and/or other appli­
cations
Some questions were however raised about this final point. Ail antibodies that were 
shown to be positive by ELISA and/or other methods, had been initially selected from 
the HybriChip analysis. Any information relative to the HybriChip negative antibodies 
was unavailable, which could result in the loss of potentially ELISA or Western blot 
positive antibodies (false negatives in HybriChip). In order to really validate our screen, 
we needed to carry a complete HybriChip/ELISA correlation study, were each and 
every hybridoma from a library would be tested by HybriChip and by ELISA.
This was accomplished by creating a hybridoma library from the immunization of five 
mice with a total of 9 antigens (Table 9). Contrary to the standard procedure, we 
decided to minimise the initial round of cell culture by at first growing the hybridomas 
on 96 well plates, without ensuring monoclonality and selecting, after a first round of 
HybriChip and ELISA screening, the five "best" samples per antigen (mother clones). 
The selected mother clones would then be subjected to monoclonality by a round of 
subcioning, where each mother clone is plated into 96 well plates at a concentration of
0.5 celis.weil"^ (subclones).
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A library of 5376 subclones was thus obtained and each of these hybridomas was 
screened by ELISA and by HybriChip. After processing and analysis of the exper­
iments, the data obtained from each screening method was compared. Antibodies 
showing positive results on both assay formats would be defined as "positive", antibod­
ies positive only on the HybriChip assay would be defined as "novel”. The presence 
of HybriChip false negatives (positive by HybriChip could be explained by several rea­
sons:
• Firstly, this result couid be caused by a critical difference in epitope-presentation 
on both assays, making the eptiope unaccessible for a particular antibody.
• Secondly, the signal of a HybriChip false negative on an ELISA assay couid be 
above the minimal threshold of 0.2 OD units, thus being selected as a positive 
binder merely based on that fact.
• Finally, and related to the previous point, ELISA assays generate single data 
points per antibody screened while each HybriChip experiment generates at least 
three. The risk of false positivity by ELISA might be statistically higher that the risk 
of false negativity in HybriChip, since one single data point can not be validated, 
or supported, by replicate values.
Table 9 shows the result of this comparison. From a first analysis of the results, we 
can see a random distribution of correlation values for the whole experiment. In order 
to get a real meaning of these results, we need to take the values generated by each 
antigen on the ELISA screens. Considering that the background noise in an ELISA 
experiment will have numerical values <0 . 2  OD, it is important to make a distinction 
between assays generating results close to these background values and those having 
values well over that threshold bar. We can divide our set of antigens into three groups: 
one containing KetB5, Ket95, HMG CoA and His-IPAPB (ELISA OD >> 0.2), a second 
with CSD SAP, 4950, IPAPBmid, IPAPBpep2 (ELISA OD < 0.6) and, finally, GST Hupf 
having a complete set of ELISA ODs below the 0.2 background mark.
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Antigen
Name
Fusion
ID
ELISA
Positives
ELISA 
Value Range
Chip/ELISA
Matches
IgG IgM Total
Correlation
Novel Chip false 
negatives
KetB5 540715 53 0.6052-1.6616 51 48 3 96.22% 4 2
Ket94 540715 15 0.7615-1.9997 13 13 0 86.67% 8 2
HMG Co A 1520 69 0.5094-1.9562 53 51 2 76.81% 0 16
OSD SAP 1520 3 0.2515-0.6053 2 1 1 66% 0 1
4950 540712 3 0.2508 - 0.4096 2 1 1 66% 1 1
GST-Hupf 540710 0 All < 0.2 0 0 0 100% 0 0
His-IPAPB 540710 7 0.3042 -1.2849 6 2 4 85.71% 0 6
IPAPB Pep2 540713 2 0.4048-0.4188 1 0 1 50% 0 1
IPAPB Mid 540713 19 0.1927-0.57 11 11 0 57.89% 0 8
Table 9. Correlation between HybriChIp and ELISA results
Overview of the results of this HybriChip/ELISA correlation analysis. The number of pos­
itive samples, the range of ELISA CDs, and correlation data for IgG antibodies are pre­
sented for each antigen. Novel samples are those antibodies (IgGs) which were positive 
by HybriChip, but were negative in the ELISA screen
For the first group of antigens, our correlation ranges from 76.81%  to 96.22% . Even 
though the number of positives for each antigen is variable (from 7 to 69), we can 
appreciate that the ELISA OD values for these antigens are all over the 1.0 O D bar. 
On the other hand the second group of antigens, which present much lower ELISA OD  
values, show a lower correlation with the chip experiment, ranging from 50%  to 66% .
The values are near the background mark ar% #he selection of positive samples is 
quite subjective. Very few samples are selected in both experiments and the chance of 
having IgM positives seems to be higher. It is interesting to notice how a good number 
of IPAPBmid positive hybridomas were selected by ELISA (19) even though their ELISA  
ODs were still close to the 0.2 cut-off value and yet, we isolated 11 positives by chip. 
We have to point out that since this antigen was a peptide, the adsorbance efficiency for 
this antigen might have been quite limited. Finally, we have the last antigen CSD-Hupf, 
which was completely negative in both the ELISA and the microarray based screening 
assay. W e can consider that this antigen showed a 100%  correlation between the 
ELISA and the chip screening (no false positives).
It is possible to conclude that the HybriChip results show a high correlation with a con­
ventional ELISA screening of hybridoma libraries. However, the lower the intensities
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of the ELISA screen, the lower the correlation. The dynamic range of the HybriChips 
is greater that for the ELISA, thus making the detection of positive samples showing 
ELISA intensities near background levels more difficult and subjective to be made (Fig­
ure 18).
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Figure 18. HybriChip/ELISA correlation: graph
Example of the correlation between HybriChip (IgG results only) and ELISA (IgG and IgM) 
for one KetB5 (A) and Ket94 (B) plate. Normalised values for each sample in the plates, 
from the chip and the ELISA analysis were plotted in a sample by sample manner. 
HyrbiChip and ELISA normalised values are shown on the left and right axes respectively.
4.2.8 Upscaling of the whole platform: 80 antigens trial
Having validated both the multiplexed immunization protocols and the microarray based 
assay, we wanted to try to scale up the platform. For this "scaling up” experiment, 
we immunized 8 mice with 10 antigens each (total of 80 antigens). Considering the 
high number of antigens injected into each mouse, it was essential to try to minimise
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immuno-focussing and immuno-dominance (Harlow and Lane, 1998) and to generate a 
wide spectrum of immune response in the animals. Therefore, after primary immuniza­
tion the animals were boosted only once on day 14, and the spleens were harvested 
on day 18. Fusion was robotically accomplished using standard protocols and indi­
vidual hybridoma culture supernatants were subsequently harvested and screened by 
HybriChip. Table 10 gives a summary of the HybriChip selected clones in each fusion, 
together with the results of their screening by ELISA and WB.
Mouse
ID
Antigens Chip
Positives
IgM
Chip
IgG
Chip
ELISA
Positives
WB
Positives
1 10 32 13 19 9 3
2 10 26 6 20 14 4
3 10 45 15 30 9 9
4 10 39 12 27 6 9
5 10 32 1 31 21 19
6 10 45 11 34 5 9
7 10 43 14 29 13 5
8 10 27 6 21 4 3
Total 80 289 79 211 91 51
Table 10. 80 antigen experiment: selected antibodies per fusion
0As shown in Table 11, mAbs were raised against 67 of the 80 antigens (83%) as tested 
by HybriChip. Of these, IgG secreting clones were raised against 61 (77.5%) of the 
targets and IgM-secreting clones were raised against 32 (40%) of the target antigens. 
Multiple hybridomas were generated from these IgG secretors, which recognised 32 
(40%) of the target antigens by HybriChip and were positive in at least one further 
immunoassay. Of the 61 IgG secretors raised against the 80 original antigens and 
identified by HybriChip, hybridomas were isolated that recognised 15 of the target anti­
gens by both western blot and ELISA; hybridomas isolated against 10 of the targets 
were positive by ELISA only and hybridomas raised against 7 of the targets were posi­
tive by Western blot only. Hybridomas positive in both the IgG and IgM channels were 
not taken into consideration since this effect might be mainly caused by a lack of mono- 
clonality in the source cell-culture plate. These samples are regarded as negative and
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are thus not selected for expansion.
Mouse
ID
Chip
Positives
Chip
IgM
Chip
IgG
EUSA
Positives
WB
Positives
Chlp/ELISA/WB
Positives
Chip/ELISA
Positives
Chip/WB
Positives
Chip Only 
positives
Negatives Missing 
WB Data
1 9 4 7 5 2 2 3 0 4 1 2
2 6 2 6 3 1 1 2 0 3 4 0
3 10 6 8 2 2 2 0 0 8 0 3
4 9 6 9 4 5 4 0 1 4 1 1
5 8 1 8 5 6 3 2 3 0 2 2
6 8 4 8 1 4 1 0 3 4 2 3
7 9 6 9 4 1 1 3 0 5 1 4
8 8 5 6 1 1 1 0 0 7 2 0
Total 67 34 61 25 22 15 10 7 35 13 15
Table 11. 80 antigen experiment: antigen specific data
Summary of results for each mouse. The figures represent the number of target antigens 
against which antibodies were raised
4.2.8.1 80 Antigens experiment: example images Figures 19, 20 and 21  show 
typical HybriChip results.
Figure 19. Antigen 1
Image resulting from the processing of antigen 1. The magnified area shows a detail of 
positive IgG and IgM samples
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Figure 20. Antigen 2
Image resulting from the processing of antigen 1 . The magnified area shows a detail of 
positive IgG and IgM samples
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Figure 21. Antigen 3
image resulting from the processing of antigen 1. The magnified area shows a detail of 
positive IgG and IgM samples
4.2.9 Determination of the most suitable chip substrate for the HybriChip plat­
form
All the experiments were carried using "home-made" slides (Drzonek, EMBL), which 
presented extremely high quality features. However, these slides lacked a proper qual­
ity control and, depending on uncontrollable events such as climatic conditions and 
human handling factors, the uniformity of quality could not be guaranteed from batch
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to batch. Having validated and upscaled the complete platform, a large scale analysis 
of available commercial surface chemistries was performed. EMBL slides and seven 
commercial chips were used for this comparison (Table 12).
All slides were treated and processed similarly. Because of their physical entrapment 
of the spotted samples into the substrate, the FAST and HydroGel slides did not show 
compatibility with our assay format. All the spots emitted a signal, and this could be 
caused by the impossibility of releasing the unbound hybridomas form the coating poly­
mer. Alternatively, it is possible that the coated antigen has a low penetration into the 
polymer, thus making the assay un-feasible. Similarly, the eSurf slides also showed 
signals emitted from all spotted samples. The explanation for this outcome using 
these slides is still unknown. Finally, the SuperAmino and SuperAldehyde microar­
rays showed very disappointing results, where the background was quite high on the 
Gy3 channel and the spot intensities were quite low.
On the other hand, the Ansorge, PicoSlide and CodeLink slides showed interesting 
results (Figure 22). Based on the visual analysis of the chips, it was observed that:
• The EMBL slides had the highest spot intensity: signals from positive samples are 
very high compared to the other slides. The experiments could be performed with 
lower amounts of secondary antibodies, since it appears that with our HybriChip 
protocols, high affinity hybridomas create a smear of label onto the slide.
Slide Producer Chemistry Interaction
Ansorge EMBL Aminosilane Electrostatic/Adsorption
PicoSlides PicoRapid Proprietary Covalent
CodeLink Amersham Proprietary Covalent
SuperAmine Telechem Aminosilane Electrostatic/Adsorption
SuperAldehyde Telechem Aldehyde Electrostatic/Adsorption
FAST Schleicher & Schuell Nitrocellulose Immobilisation/Trapping
HydroGel Perkin Elmer Polyacrylamide Immobilisation/Trapping
eSurf LifeLineLabs Proprietary Polymer Covalent
Table 12. Comparison of substrate chemistries
Properties of the different modified slides used for the selection of the most suitable solu­
tion for the HybriChip platform
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PicoSlide and EMBL slides showed very low background: this is an advantage for 
the identification of positive hybridomas, since a low background creates a clear 
division between a spot and its environment.
CodeLink slides present the best spot geometry: while for the other two slides 
spots tend to present variable diameters and, in several cases, to be charac­
terised by a "doughnut" shape, spots in the CodeLink chemistry are very consis­
tent in diameter and shape (not shown).
Figure 22. Comparison of substrate chemistries
All slides were coated with 5 of an antigen and blocked with 2.5% BSA in PBS. Super­
natants were spotted onto each slide and the generated microarrays were processed with 
the standard protocols. Each slide was scanned using the the same laser parameters 
100% power, 130 and 140 pmt gain for Cy3 and Cy5 respectively.
A - EMBL chemistry 
B - PicoSlide 
C - CodeLink
It was then decided to use both the EMBL and the PicoSlide chemistries for our plat­
form, where the EMBL slides are commonly used and, for projects involving critical 
antigens, both solutions are used in parallel. This decision was based on economical 
reasons, since the Ansorge slides are obtained free of charge (or at production costs) 
while the PicoSlides are quite expensive (-15 €/slide).
A similar analysis had been previously performed, whereby several trimethoxysilane 
based substrates were determined as being the "best" solutions for arraying proteins 
(Kusnezow et al., 2003). It is difficult to compare both experiments, mainly because of
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the assay formats. While the previous study was performed using standard antibody 
microarray protocols (antibodies spotted directly onto the surface), we are perform­
ing "reverse phase” antibody screening, therefore chemical interactions and properties 
might be different. However, we can suggest that, generally, silane based chemistries 
can be considered as the most suitable substrates for protein arraying.
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5 Hy-CAT©
Protein microarrays are a technology arising from the well established field of DNA 
microarrays. Because of this, the technology used to produce DNA chips, such as sur­
face chemistry, liquid handling robots, spotters, hybridisation tools and image acquisi­
tion software, can be easily adapted to generate and analyse protein based microar­
ray experiments. Considering that DNA microarray analyses require several statistical 
methods, normalisations and clusterings to obtain relevant information about the differ­
ences in gene expression patterns, analytical software has proved to be "bulky" for the 
analysis of protein microarray data.
Contrary to DNA microarray experiments, not all samples on a protein microarray will 
generate a signal. Therefore, as a first procedure, samples not emitting signals must be 
removed from the data set. The remaining samples need to be analysed and selected 
in order to remove all false positives, low affinity species and cross reactive antibodies. 
This analysis procedure requires a specific set of algorithms in order to be routinely 
performed. We have therefore written a software application, Hybridoma Chip Analysis 
Tools (Hy-CAT), which is able to quickly perform all these functions and to quickly and 
efficiently identify all positive monoclonal antibodies in a screened hybridoma library.
5.1 The Chip analysis process
The analysis of HybriChips using the HyCAT application is divided into two steps:
1. Gathering of the general chip information and selection of normalisation and fil­
tering parameters: via a graphical user interface (GUI), the user enters general 
information about the chip, such as the name of the antigen (antigenlD), the fu­
sion identifier (fusionID) and the number of replicates for each spot. Via the same 
GUI, the user can select the normalisation method to be used, together with the 
range of spot diameters to be used for the spot selection procedure.
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Figure 23. HyCat
2. Gathering of the chip data for analysis: using conventional microarray analysis 
applications, information such as "spot total intensity", "background”, "ratios", 
"standard deviations” and other statistical data will be retrieved for each single 
spot, generating a massive amount of data. As previously mentioned, the anal­
ysis of HybriChips does not require all of this data, therefore a method for the 
selection of the relevant data for each sample is necessary. HyCAT’s first proce­
dure is to facilitate this selection, via a easy-to-use GUI. The user loads a data file 
into the application and selects the relevant data fields for the analysis. HyCAT 
will analyse the chip data using the parameters entered in point 1 .
These two steps being completed, HyCAT will perform the complete analysis of the 
microarray data, with the following sequence of events:
• Filter-out all samples that do not fit in the diameter fork: all spots having a di­
ameter below or above the diameter range will be removed from the analysis. 
Dust, scratches, heavy background can cause unspecific signals onto the slide, 
therefore these have to be eliminated to avoid selecting false positives.
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• Normalise all replicate spots to generate a single value per sample: one single 
parameter per HS has to be used for the analysis
• Normalise all spots: a relevant statistical set of data has to be used for the anal­
ysis of the arrays
• Determine the distribution of spots by intensity ranges
• Graphically display this intensity distribution and prompt the use to select a filter 
value: a binomial distribution should be obtained from the analysis where the 
high-intensity peak represents the distribution of intensities from spots containing 
positive hybridomas. The user is prompted to enter the normalised intensity value 
(threshold) to be used for the retrieval of these positive hybridomas (Figure 5.1)
m
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Figure 24. Distribution of intensities
Filter-out false-positives, ie those samples belonging to the wrong fusionID: see 
section 5.1.2
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Retrieve and display all IgG and IgM samples having a normalised intensity value 
equal or greater than the user-selected threshold (Figure 25)
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Figure 25. Results table - single antigen
Generate a text string ready for import into a LIMS SQL database.
5.1.1 Normalisation methods
The most important steps into the chip analysis are the normalisations of the replicate 
samples and of the complete chip data. Two statistical methods are used for these key 
steps. The first one is based on the calculation of the percentile contribution of each 
spot to the total intensity of the chip. Replicate intensities are averaged, to obtain an 
average intensity for each sample {\r) and each 1^  value is divided by the sum of the 
intensities of the chip (Equation 1 ).
The second, which is the default method, calculates the median of the median intensi­
ties of each set of replicates {\r) and then divides this resulting value by the median of 
all the microarray’s \ r  values (Equation 2).
F. De Masi 85 9606101
I r —
_______________________ 5 HY-CAT©
E l /n
^  ~  ■ s r ^ iV  r  ^El
Equation 1. Percentile contribution normalisation
where Ir  is the average of the intensities for each set of replicates, H is the normalised 
value of the sample, I is the total intensity of each spot, n is the number of replicates and 
N is the number of spotted hybridomas
While the first method is fast and reliable when we analyse a "single antigen” exper­
iment, it becomes less solid in case of several antigens being used to immunize an 
animal. Each microarray will produce a different "total intensity”, thus the results of 
each microarray will need to be re-normalised against the whole set of results. One 
array could have a set of positives lying at the 1 -2 % range, while the next, with more 
intense signals, could present positives in a range of 5-7%. With this method, it is not 
possible to determine a general rule by which the positivity of one sample can be as­
sessed directly from its normalised intensity. Furthermore, results between slides can 
not be directly compared to each other.
Another limitation of this method is that arithmetic averages are sensitive to single 
events. This limitation is of particular relevance for the normalisation of the spotted 
replicates. In the case of a missing spot (caused by a spotting error, for example), the 
final value of that set of replicates will be dramatically modified. For example, a set 
of 4 replicates with values {1, 1.5, 1, 2 }, will have an averaged intensity of 1.375. By 
insertion of a spotting error, the values of the same set of replicates could become {1 , 
1 .5, 0, 2 }, resulting in a new averaged value of 1.125, thus modifying the properties of
H
In^medianil
I r
median^ I r
Equation 2. Median Intensities Normalisation
where Ir  is the median of the median intensities for each set of replicates, I  is the me­
dian intensity value of each spot, H is the normalised value of the spot, n Is the number of 
replicates, N  is the number of spotted hybridomas
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the particular sample. However, the same set of replicates will have a median value of 
1.25. By applying again the same spotting error, thus having a zero value for the third 
replicate, the median value for this modified set would still have a value of 1.25, thus 
maintaining the properties of the sample.
Another motivation for using the "median of medians" normalisation method is that it 
can allow for a fast comparison of results between different chip results. Since all 
samples are normalised against the median value of a microarray, all samples having 
an intensity value close to the median, will have a normalised value of ~1. All chips 
will therefore have a normalised intensity value of 1 for all samples showing average 
intensities, thus showing values much greater than 1 for high intensity samples, ie pos­
itive monoclonal antibodies. Since the method is independent of a chip’s total intensity 
calculation, we can thus consider that once normalised, each normalised value will 
represent the same "sample quality” in each analysed chip. This allows for the deter­
mination of value boundaries for the characterisation of samples. We have postulated 
that all samples showing a \r value lower than 3 are negative; if the Ij? is between 3 and 
2 0 , the sample is "likely to be positive”, meaning that the antibody might be functional in 
ELISA and/or in Western blot; if the I/? is greater than 20, we can consider the sample 
to be a "sure positive”, ie the sample will be functional in ELISA and/or Western blot.
However, this normalisation procedure has its own limitation. When a chip contains 
a large number of values equal or very close to 0 , the median of that particular chip 
will, in its turn, be equal or close to 0. When we then divide each spot’s value by the 
chip’s median (~0 ), the normalised values of the totality of spots will be too high, or 
impossible to determine (division by zero), to be analysed. To overcome this problem, 
the 80-90th percentile value is used as the normalisation factor, instead of the median 
of the chip.
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5.1.2 Filtering of false positives
This quick procedure became necessary with the aim of analysis automation. Since, 
when spotting more fusions onto a single slide, it was common that samples from 
the wrong fusion would appear as positives in the final results list (heavy background 
on parts of the slide, scratches, dirt, cross reactive antibodies, etc), it soon became 
necessary to remove those samples from the displayed results.
The system used in HyCAT is quite simple and consists in using the antigen’s fusionID 
(see section 5.1, page 82). When the selection of positive samples has been done 
by the analysis process, all samples not having the correct ’’fusionID” in their unique 
identifier (samplelD, see Appendix 7.1) will be discarded.
5.2 Unique samples selection: elimination of cross-reactive species
One of the most important requirements of our screening system is to isolate those 
hybridomas that are specific for one and only one antigen. Unfortunately, several sam­
ples might contain elements that are able to generate a signal on several or all of the 
microarrays. Therefore, these samples might appear to be good positive monoclonals 
while we analyse the chips one at a time, but are then found to be cross-reactive. It is 
then important to cross reference each set of hybridomas against all chips, and to fitter 
out only those that are specific for one antigen only.
HyCAT has been implemented with a tool that is able to quickly and specifically achieve 
this task. By loading a set of text files containing the samplelD of each positive antibody 
isolated for each antigen (1 file per antigen), HyCAT will generate a list of ’’uniques” 
that will then be used to select the specific positive hybridomas from the cell-culture 
plates. For each file loaded into the program, each samplelD will be compared with the 
samplelDs present in the other files. If no matching samplelD is found, this sample will 
be stored as a "unique” sample.
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5.3 HyCAT’s future prospects
Even though HyCAT is currently used as the standard data analysis tool for the mon­
oclonal antibodies production platform, there are still some features that should be 
implemented. Some can be defined as non-indispensable, such as:
• Direct conversion of results files to comma delimited file, ready to use (removing 
scanner specific file headers).
• Replacement of the FusionID number with the antigen name
• More normalisation procedures, such the mentioned 80-90th percentile method
• Faster code, to decrease calculation time
• Help manual
Other features are, however, highly required, such as:
• Spot image extraction, to cross-link with the results table. This is necessary to 
validate each positive sample, since it might happen that a particular "high inten­
sity” sample is nothing else than an unspecific signal that matched the filtering 
parameters
e Database functionality, for the storage of all analyses and results, and which could 
be directly linked to the LIMS system
• Direct communication with the cell-culture robot, to allow for a direct cherry- 
picking of the positive hybridomas
However, these last implementations would require a more extensive knowledge of the 
programming language (Visual Basic 6 .0 ) and the time required to code these features 
would be too long. Therefore, it was decided to leave the application as it is, until all of 
these extra tools could be easily implemented.
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6 Discussion and Conciusions
6.1 Novel protocols for the production of monoclonal antibodies
The importance of detection reagents, and especially of monoclonal antibodies in 
biomedical research, has been driving several laboratories towards the design and 
implementation of novel protocols for their production. A common feature that has 
characterised these efforts is the need for a truly high-throughput method, which could 
alleviate production facilities from heavy labour, time and costs. With the opening of 
a Monoclonal Antibodies Core Facility in the year 2000, the EMBL decided to par­
ticipate in this particular area. In order to obtain a high-throughput method for the 
production monoclonal antibodies, it had been decided to specifically focus on those 
areas of monoclonal antibody production that were identified as major bottlenecks in 
the standard protocols. As described in the introduction (page 26), these bottlenecks 
were identified as being the fusion and cell culture steps, together with the hybridoma 
screening methods. It was also decided to develop novel immunization protocols to 
optimise the immune responses of the host animals, thus minimizing the timeline of 
antibody generation. A general working plan was formulated, which comprised three 
steps:
1. Immunization protocols: we considered that if one mouse could respond to one 
antigen, it should specifically respond to more. This was an obvious consideration 
since it had already been common practice to immunize animals with tissue slur­
ries, or with predigested proteins, thus technically having a mixture of antigens. 
These can however be considered as mixtures of "unknown" antigens (slurries) or 
as a unique antigen (digested peptides). We therefore envisaged using cocktails 
of known antigens (independent of their origin) to immunize each mouse. Our 
goals were to be able to immunize each animal with at least 1 0  different antigens.
2 . Fusion and Cell Culture methods: since all the tissue culture steps are long, 
repetitive and error prone, we considered modifying a commercial robotic platform
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to perform the relevant steps of hybridoma culture. Such an automated approach 
would be able to perform the fusion process of splenocytes to myelomas and to 
generate and maintain the single cell cultures derived from such a fusion.
3. Hybridoma screening: the initial idea for the improvement of the screening method 
was based on an automated ELISA platform, using the aforementioned robotic 
platform. However, this solution presented heavy limitations, and of speed and 
costs. Large scale ELISA screens would have been time-consuming, even with 
automation, and the quantities of plastic-ware and reagents would have been 
enormous. Having considered several alternatives or solutions for this problem, 
we decided to test a microarray approach, which could enable us to screen sev­
eral thousands of hybridoma supernatants quickly and using less materials.
Figure 26 compares the standard protocols of antibody generation with our designed 
strategy.
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Production of mAb
Conventional method 
(1 specific mAb in variable 
time - 6-9 months)
Our method 
(1 specific Ab in 60 days)
Immunise with 
one antigen
All cell culture work 
done manually
Immunization
ELISA of all hybridoma 
supernatants, followed by 
Western blot analysis and 
isotyping of the ELISA 
positive clones
Myeloma B-cell
Hybridoma cell
Cell culture; Produc­
tion of hybridomas 
by fusion of B-cells 
and myelomas
Screening for 
hybridoma clones 
secreting specific 
mAbs
Immunize with 8-10 
antigens simultaneously
Robots perform all 
cell culture work
1.
High throughput prescreenig; 
all hybridoma supernatants 
are matched against each 
antigen using microarrays 
(isotyping is included).
2.
ELISA and Western
blot analysis of the positive
hybridomas
Figure 26. Production of monoclonal antibodies
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6.2 HybriChips: establishment of a screening platform
The experience gained in the development and optimization of a protein microarray 
platform allowed us to design a screening tool that could be used for the analysis 
of thousands of samples obtained from the process of creating monoclonal antibody 
secreting hybridomas. Our goal was to replace a conventional ELISA screen with a 
microarray based assay in order to accelerate the selection of monoclonal antibodies 
for an extensive library of hybridomas. Several possibilities for designing our screening 
method were available (Haab, 2003; Templin et al., 2 0 0 2 ). We could perform a sand­
wich assay, which involves the spotting of the hybridoma supernatants (HS), followed 
by the hybridisation of the array with the purified antigen. The binding of the antigen to 
an attached monoclonal antibody would be then detected by hybridizing the array with 
a second monoclonal against the specific antigen (Figure 27 A). While this approach 
appeared to be promising, we determined that it presented two important flaws. First, 
we might have been trying to generate a novel monoclonal antibody against an antigen 
for which there are no existing recognition molecules. It would then be impossible to 
perform a sandwich assay. Secondly, we might have generated a certain number of 
monoclonals that recognise the same epitope as the sample we would use for the de­
tection of the interaction. This would mean that these samples could not be detected 
because of the non-availability of the binding domain. We decided that this strategy 
would be of no use for our project.
A second possibility for our screen would involve again the spotting of the HS library 
and the screening using a previously labelled antigen. This could be done using stan­
dard Cy3 or Cy5 labelling or by biotinylation of the antigen and detection with labelled 
streptavidin (Figure 27 B). However, we again considered that this approach could have 
presented some problems. The direct labelling of proteins with fluorophores is a long 
process and the labelling efficiency is sequence dependent (Mujumdar et al., 1993). 
Due to the binding of the fluorophore molecules to primary amines on the antigen, 
different antigens would be heterogeneously labelled. Furthermore, the fluorophore
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molecules might have been attached to a specific epitope, thus lowering the affinity 
or, in some cases, inhibiting the interaction with the antibody through steric hindrance. 
These effects could also be seen in the case of the biotinylation of the antigen .
The final option we identified for the design of the array is based on the spotting of the 
antigen onto the slide and the hybridisation of this array with the HSs. The detection of 
the interaction between an antibody and the immobilized antigen would be done using a 
commercially available labelled secondary anti-mouse Ig monoclonal (Fig 27 C). This 
strategy gave us the idea that we could perform direct isotyping of the monoclonal 
antibodies by using differentially labelled (Cy3 and Cy5 for example) anti-mouse IgG 
and anti-mouse IgM secondary antibodies. However, this design presents a major 
problem, which is that we might have a maximum of 1 0  antigens per mouse, and a 
total of 1920 hybridomas per fusion. Therefore, we would create a relatively small 
array with 1 0  samples, and would need an extremely large number of chips in order to 
screen all the hybridomas. .
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Figure 27. Possible strategies for a microarray based screening platform
A - Sandwich assay: hybridoma supernatants are spotted onto the modified glass. The 
arrayed supernatants are hybridised with the target antigen and the resulting interaction is 
detected with a paried specific antibody.
B - Direct labelling of the specific antigen: same procedure as in point A, whereby detec­
tion of the antibody/antigen binding is done by directly labelling the antigen.
C - Spotting of the antigens used for immunization. Hybridisation with single hybridoma 
supernatants. Detection by labelled secondary anti-mouse IgG antibody
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We were then faced with the problem of having to design a novel microarray strategy. 
By immobilizing the HSs on the slide, we could screen extensive libraries of hybrido­
mas in one single experiment, while with the immobilization of the antigens we could 
perform direct isotyping of the positive samples, directly in the same screening ex­
periment. Combining these two properties, we developed a novel antigen microarray 
screening method (HybriChip). In this assay, an antigen chip is generated by coating 
an am inosilane treated slide with a single target antigen. Hybridoma culture super­
natants from a fusion are spotted as a microarray onto the antigen chip. After probing 
with a suitable fluorescently labelled secondary antibody, positive hybridomas are iden­
tified in a microarray scanner. The isotype of the bound antibody can be concomitantly 
determined by probing the antigen chip with mixtures of isotype-specific secondary 
antibodies, such as CyS-conjugated anti-mouse IgM and Cy3-conjugated anti-mouse 
pan-IgG (recognising all mouse IgG isotypes). Different antigen chips can simultane­
ously be spotted in parallel with the same hybridoma culture supernatants, allowing for 
a rapid automated assay of multiple antibodies against many target antigens. (Figure 
28).
IS
" k  ■»%
Figure 28. Hybridoma screening strategy
A - A chemically modified slide is homogeneously coated with purified antigen. Hyr- 
bidoma supernatants are succesively spotted onto this antigen layer.
B - The microarray containing the spotted hybridoma supernatants is hybridised with a 
solution containing CyS labelled anti-mouse IgG and Gy5 labelled anti-mouse IgM.
C - Isotype specific signals (green: IgG, red: IgM) are detected from the spots presenting 
hybridoma supernatants containing monoclonal antibodies specific for the coated antigen
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6.3 HybriChips - the results
The validity of the described screening platform has been established experimentally.
The first part of the project was focussed on feasibility experiments, where we demon­
strated that:
1. Coating of a chemically modified glass slide with a homogenous solution of anti­
gen: using the chemical properties of the aminosilane chip chemistry, it is possi­
ble to apply an antigen layer onto the slide (Section 4.2.2).
2. Detection of spotted antibodies: because of the screening format we wanted to 
use, it was crucial that only antibodies specific for the coated antigen were de­
tected on the microarray. This means that antibodies should not be able to un- 
specifically bind onto the antigen, or to free aminosilane active sites. Experiments 
involving characterized antibodies and hybridoma libraries have shown that an­
tibodies are able to specifically recognize the coated antigen. Furthermore, no 
cross-reactivity or direct binding of antibodies to the aminosilane coating can be 
detected (Sections 4.2.3 and 4.2.4).
3. Detection of antibodies from hybridoma libraries generated by multiplexed immu­
nizations: in order to obtain a high-throughput monoclonal antibody production 
platform, a fast, specific and highly sensitive screening method is required. We 
have shown that using a microarray assay, it is possible to select monoclonal an­
tibodies specific for single antigens, from a unique hybridoma library generated 
from a multiplexed immunization (Sections 4.2.54.2.6).
4. Direct isotyping of the detected monoclonal antibodies: because of the format 
of the assay, direct isotyping of the monoclonal antibodies could have been pos­
sible by using, as detection method, differentially labelled secondary antibod­
ies. We used Cy3-anti-mouse IgG and Cy5-anti-mouse IgM antibodies. The 
selected positive antibodies were confirmed by a second round of isotyping, in an
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ELISA format and using a commercially available strip assay (McDougal et al., 
1983){Section 4.2.4).
These results show that the designed assay format can be used to screen extensive 
hybridoma libraries. All HybriChip selected IgG monoclonal antibodies in these ini­
tial experiments were proven to be positive by ELISA and/or Western blot. Further­
more, antibodies selected with this screening have been shown to be functional in 
more demanding experiments, where for example, the antigen needs to maintain a na­
tive conformation. These results validated our strategy and established the use of the 
HybriChips as a powerful primary hybridoma screening procedure.
However, before using this strategy as a routine primary screen, an higher level of 
validation was needed. In the first part of the project, only those IgG monoclonal anti­
bodies that were selected by HybriChip were further analysed by ELISA and Western 
blot. No further information was available for IgM antibodies and for HybriChip negative 
samples. In order to eliminate the risk of "missing" false negatives, a large compari­
son between HybriChip and ELISA had to be performed to determine the correlation 
between both assays. From this experiment (Section 4.2.7), we were able determine 
that both assays are able to identify the same sets of antibodies. Correlation values 
were elevated (>75%) in the case of antigens were a statistically relevant number of 
antibodies where generated and their respective ELISA OD values were well above the 
background levels (0.2 OD). Other antigens, for which few antibodies were selected, 
seemed to have lower correlation values. Due to the low sample size however, statisti­
cal significance cannot be established for this data. It is important to point out that even 
though there are few antibodies against these antigens, we were still able to specifi­
cally detect them by HybriChip and ELISA (Table 9). We can then conclude, from these 
results and considerations, that the HybriChip approach can be used as an effective, 
fast and high-throughput primary screen.
To test the complete high-throughput monoclonal antibody production platform, a large 
scale experiment was carried out. Eight mice were immunized each with 10 antigens
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(Section 4.2.8). The fusions were robotically performed and the complete hybridoma 
library (15320 samples) was screened by HybriChip. ELISA and Western blot analy­
ses of the selected IgG antibodies were performed to validate the HybriChip results. 
Monoclonal antibodies were selected against 67 of the antigens. Of these, 25 were 
positive by ELISA and 22 by Western blot (Table 11). We achieved an overall suc­
cess rate of 40% for antibodies identified with HybriChip that tested positive at least 
one other immunoassay, and 28% for antibodies that were functional in at least one 
immuno-application. The disparity between HybriChip and ELISA in this large scale 
production of monoclonal antibodies partially reflects the increased sensitivity of the 
HybriChip (Tonkinson, J.L., h t tp : / /w w w .d e v ic e l in k .c o m / iv d t /a r c h iv e /0 3 /0 3 /0 0 1 . 
h tm l). In this experiment, the threshold for HybriChip-positive clones was set too low; 
the correlation between HybriChip and ELISA approached 100% when the threshold 
was increased. Thus, clones testing negative by ELISA due to factors such as low an­
tibody concentration in the supernatant or the presence of an antibody of low binding 
affinity (both are plausible causes considering the short immunization protocol), gave a 
positive result by HybriChip. In addition, the conformation of proteins on the HybriChip 
substrate may render available antibody-binding sites that are masked by adsorption 
onto the polycarbonate substrate used in ELISA. In support of this possibility, several 
of the proteins negative by ELISA were subsequently found positive by Western blot. 
Because of the lack of Western blot data for 15 of the antigens, it is not possible to 
speculate about the correlation between HybriChip and Western blot.
6.4 Conclusions
We have developed a fast, economical, high-throughput, method of hybridoma gen­
eration which with a simple scale-up could help to alleviate the current bottleneck in 
mAb production. Comparison with similar studies is difficult as others have focused 
on the production of antibody serum titre (Chambers and Johnston, 2003; Field et al., 
1998; Pizza et al., 2000) as opposed to the isolation and production of hybridomas.
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uompared to the best of these serum-titre studies (Chambers and Johnston, 2003), 
our method is about half as successful as the 80% success rate achieved there. Im­
provements may be possible by lengthening the immunization protocol or using genetic 
immunization, which may be more effective in attaining a suitable response against a 
higher proportion of the target antigens (Chambers and Johnston, 2003).
Our method represents a qualitative improvement over the ELISA, since clones se­
creting antibodies with different isotypes can be selected at the primary screen. IgM 
isotypes are often more useful to investigators for fluorescence-based assays such as 
FACS analysis or immunofluorescence, but this isotype is almost useless for assays 
involving protein-A as a detection reagent, most notably immuno-gold labelling (elec­
tron microscopy) and immunoprécipitation, due to their lack of affinity for protein-A or 
protein-G. IgM isotype antibodies are also notoriously difficult to purify and in these two 
cases IgG isotypes are more desirable.
Moreover, the ability to assay supernatants from the same fusion against multiple tar­
gets simultaneously enables us to perform limited epitope mapping on-the-fly at the 
primary screening stage. This level of differentiation in the primary screening assay fa­
cilitates the differentiation and isolation of hybridomas secreting mAbs specific for (for 
example) phosphorylated and non-phosphorylated peptide antigens.
6.5 HybriChips; future prospects
6.5.1 Improvements to the platform
This presented novel platform for the production of monoclonal antibodies is now used 
as a well established method by the MAC F at the EMBL. Other than serving the internal 
demands of the institute, it also functions as a commercial entity (HybriCore) for non- 
EMBL laboratories. However, this method can still be improved and accelerated:
1. Immunization protocols: immunization protocols could be optimized in order to 
increase the efficiency of the immune response into the hosts. We obtained mon-
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oclonal antibodies specific against 67 of 80 antigens with a 24 days immunization 
protocol. It should be possible, by testing different host lines or finding stan­
dard parameters for the contents of the antigen mixture to increase this response 
so that it approachesto 100%. Genetic immunisation (Chambers and Johnston, 
2003) should also be tested.
2. Fusion procedure; the possibility of performing the fusions of B cells with myelo­
mas using a robotic method allows for 8  fusions to be done simultaneously. How­
ever, it has been seen that the fusion efficiency of the robot cold be increased (still 
lower than a manual fusion). This improvement to the procedure could allow for 
the generation of a higher number of monoclonal antibody-secreting hybridomas.
3. Automation of the production of the HybriChips: manual preparation of the mi­
croarrays is time consuming and is influenced by external factors, such as room 
temperature, humidity and labware calibration. Automation of this step could re­
move some of the variations in the coating efficiency and accelerate the complete 
procedure. The slides could for example be located in a fixed position, where dif­
ferent solutions and reagents could be dispensed onto them. Furthermore, if 
done into a climatically controlled location, binding efficiencies should be con­
stant.
4. Screening of the microarrays: it would be very important to use the potentiality of 
the available scanning hardware (four lasers) to extend the isotyping screen. It 
could be possible to use differentially labelled secondary antibodies specific for 
the various IgG subclasses. However, the availability of such secondary antibod­
ies is currently very limited.
5. Selection of positive antibodies: Hy-CAT should be implemented with more nor­
malization methods and faster algorithms. The possibility of sending the list of 
selected antibodies directly to the robot controlling software for the cherry-picking 
of the clones is a necessary feature to be implemented into the software.
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6.5.2 Projects
Large-scale proteomic projects have so far been hampered by the lack of complete 
libraries of monoclonal antibodies raised against complete cellular proteomes. The 
generation of such libraries would be a very committing and financially challenging 
project if performed using conventional methods of antibody production. At optimal 
conditions, our platform could generate antibodies specific against 3000 antigens per 
year. Currently, the MACF is processing 600-700 antigens per year. Because of this 
truly high-throughput method, the MACF is becoming a major player in an all-European 
consortium, the European Proteomics Initiative (EPI). The aim of this consortium is to 
establish a pipeline of monoclonal antibodies specific for the human proteome. It is 
hoped that, with a unified effort and combination of various expertise, such a project 
would be feasible. The scientific community would be presented with the opportunity to 
have unlimited availability of detection reagents for their projects and, hopefully, a full 
human proteome analysis could be done.
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7 Appendix
7.1 Array definition: automated generation of samplelD and sam­
ple coordinates
Hy-uAT contains a feature that allows one to easily create the files needed by the 
spotters to generate an array list. For the user to be able to track his samples on 
the chip, a grid definition fiie is created, where all samples are listed relative to their 
geometrical position. In order to create such a file, the spotter software requires a listing 
of all the samples present in each well of the plates used for the spotting procedure. 
Considering that the source plates are standard 96 wells and that the spotter uses 384 
wells plates, the mapping of the samples in the plates might not be easy. The transfer 
of samples from one plate format to the other dramatically changes the layout of the 
IDs presented to the spotter. With a simple procedure, this can be easily achieved by 
Hy-CAT.
The first step done by this feature is to populate the source 96 well plates with unique 
IDs. After the users enters the number of plates used, each sample in each well will be 
identified in the following manner:
Fusion#~Plate#Row#Column#
where the Fusion# is determined by the number of plates used. Each fusion procedure 
will generate twenty 96 well plates. Therefore, the first 20 plates will be Fusioni, plates 
21 - 40 will be Fusion 2 and so on. So, as an example, the fist sample will be identified 
as 1-1A1 and the second will be 1-1A2. A graphical interface can be loaded to modify 
these IDs or to mark empty wells. Transfer of samples from 96wp to 384wp is done 
following the zig-zag method, where samples from plate 1 will start from well A1, plate 
2  will start at well A2 , plate 3 at B1 and plate 4 at B2 (Figure 29)
This procedure wiil output a comma deiimited fiie (*.csv) containing the following struc­
ture:
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96-well piatos
96-pipetto fobol B
► czigzag
96 pipolts robot 
dockwise ^
384-well plale
384 well plain
Figure 29. Plate transfer methods
Each 384 wells plate contains four 96 wells plates. Two methods of transferring 96 wells 
plates into the 384 wells plate exist:
- The zigzag method
- The clockwise method
Plate Row Column ID Name
1 1 1 1-1A1
1 1 2 1-2A1
1 2 1 1-3A1
1 2 1 1-4A1
a ■ ■ a a a a a a
5 1 1 2-1A1
a • a a a a
Last Fusion Plates 12 24 Last Fusion ID -20H12
Table 13. Output format for sample Identification
The "Name" column is empty, for the user can add sample specific comments, such as 
"Positive Control" or other
This file is then loaded into the spotter software, where it will be used to generate a map 
of the spotted samples that follows the specific spotting procedure used, and which will 
be used for the identification of the spots at analysis time.
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7.2 Patent application (GB0308976.0 - WO 03/089471 )
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1
Method for producing monoclonal antibodies
The present invention relates to methods for producing monoclonal antibodies. In 
particular, the invention relates to high thioughput methods for producing monoclonal 
antibodies more rapidly than conventional methods.
5 The development o f monoclonal antibody-producing cell lines by somatic fusions of B 
lymphocytes with myeloma cells was first described by Kohler and Milstein over 25 years 
ago (Kohler & Milstein, 1975). Since then, monoclonal antibodies have played a central 
role in the exponential growth o f our understanding of human physiology, biochemistry 
and genetics. Monoclonal antibodies are versatile and sensitive tools for detecting and 
10 localising specific biological molecules. Monoclonal antibodies can be made against any
cell molecule, enabling that molecule to be identified, localised and purified. In some 
cases, monoclonal antibodies also help identify the function of the molecules to which they 
bind.
The diagnostic and therapeutic potential o f monoclonal antibodies was also quickly 
15 realised after the hybridoma technique allowed their development in the mid 1970s.
Monoclonal antibodies have become key components in a vast an ay o f clinical laboratory 
diagnostic tests. In addition, a large number of licensed drugs contain monoclonal 
antibodies and vast numbers of drugs in development are monoclonal antibodies. The 
clinical use of monoclonal antibodies has been improved by the development of chimeric 
20 and âüly humanised monoclonal antibodies which minimise side-effects in patients.
However, despite the central role o f monoelonal antibodies in these developments in 
medicine and molecular biology, the process for producing and screening monoclonal 
antibodies has changed little since it was first developed by Kohler & Milstein in the mid- 
1970s. The approach most often used to produce a monoclonal antibody against a specific 
25 antigen requires a series of immunisations of mice or rats with an antigen over the course
of several weeks to enhance the activation and proliferation o f mature B cells producing 
antigen-specific antibodies. Multiple mice are generally immunised and are tested 
periodically for the presence of relevant serum immunoglobulin titres prior to somatic 
fusion. Following fusion, the supernatants of hybridomas are screened using 
30 immunoassays to identify monoclonal antibodies with a high specificity for the antigen.
The time frame required for developing a monoclonal antibody using this approach is 
generally 3 to 9 months.
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The development o f RIMMS (repetitive, multiple site immunisation strategy) has enabled 
somatic fusions to take place just 8-14 days after tlie initiation of immunisation (Kilpatrick 
et al, 1997). The supernatants of the hybridomas produced can then be screened using 
standard immunoassays, allowing a monoclonal antibody against a specific antigen to be 
5 isolated much more quickly
However, even using RIMMS, the production and screening of monoclonal antibodies 
against large numbers o f different antigens requires considerable time and resources. As 
more and more novel proteins are discovered, there is a need for faster and more efficient 
methods for producing and screening monoclonal antibodies against these proteins, in 
10 order to allow their further characterisation.
Summary of the invention
Accordingly, the invention provides a method for producing a monoclonal antibody, said 
method comprising the steps of;
a) introducing at least one candidate antigen into an animal;
15 b) recovering antibody-producing cells from said animal and rendering these cells into a 
single cell suspension;
c) generating an immortalized cell line from said single cell suspension;
d) screening the supernatant of said immortalized cell line against a protein chip on which 
the candidate antigen is displayed; and
20 e) selecting as said monoclonal antibody, an antibody that binds to said candidate antigen.
The method of the invention has considerable advantages over the methods o f producing 
monoclonal antibodies that are currently available. As already discussed, current methods 
for producing monoclonal antibodies against more than one antigen involve laborious 
immunisation and isolation protocols for each individual antigen. In contrast, in the method 
25 of the invention, the animal may be injected with multiple antigens resulting in the 
simultaneous production o f monoclonal antibodies against multiple antigens and increasing 
the speed and efficiency o f monoclonal antibody production. The use of a protein chip in 
the method of the invention accelerates the process of screening to detect monoclonal 
antibodies that bind to the antigen or antigens with which the animal has been injected. In 
30 addition, the protein chip is more sensitive than conventional screening assays, such as 
enzyme linked immunosorbent assays (ELISAs), resulting in an improved detection rate 
for slow secreting hybridoma cells which would be missed using conventional screening
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methods. Additionally, the use of a protein chip in the method o f the invention enables 
each supernatant to be screened multiple times against an antigen and uses only a fraction 
of the amount of antigen required for a single screening in a conventional screening assay 
such as an ELISA. For example, each supernatant can be screened in duplicate, triplicate or 
5 quadruplicate against an antigen.
The animal in step a) of the method o f the invention may be any non-human mammalian 
animal. Preferably, the animal is a mouse, rat, rabbit, hamster or guinea pig. Preferably, the 
animal is a mouse.
The candidate antigen in step a) is preferably a purified candidate antigen. Either a purified 
10 candidate antigen or a mixture o f purified candidate antigens may be introduced into the
animal. By “purified candidate antigen” is meant that the antigen is a homogenous 
preparation o f antigen that is substantially free from any other components. By “a mixture 
of purified candidate antigens” is meant that more than one purified antigen is present in 
the composition used for immunisation, but that the preparation is free from contaminating 
15 components for which there is no intention to elicit the production of antibodies. For 
example, although using conventional procedures, an animal may be immunised with 
multiple antigens simply by immunisation with homogenised tissue, such immunisation 
does not represent immunisation with purified candidate antigens as this is defined herein, 
since the antigens would be contaminated with cellular debris.
20 Any number of purified candidate antigens may be introduced into the animal. Preferably, 
between 1 and 50 purified candidate antigens are introduced into the animal. Preferably, 
more than one purified candidate antigens are introduced into the animal. For example, 2, 
3, 4, 5, 6, 7, 8, 9, 10,15, 20, 30, 40, 50 or more than 50 purified candidate antigens may be 
introduced into the animal. The antigens may be introduced simultaneously, in the sense 
25 that they are all mixed together. Alternatively, the antigens may be introduced separately 
one after the other. The introduction of different antigens may be separated by a time 
period o f days. Preferably, the period separating the introduction of different antigens is 
less than 48 hours, preferably less than 24 hours. Preferably, the method of introduction 
involves injection o f the antigen(s) into the animal.
30 By the term “candidate antigen” is meant any substance capable of inducing an immune
response in an animal when that candidate antigen is introduced into the animal. The term 
therefore includes proteinaceous substances and non-proteinaceous substances.
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Proteinaceous substances which are antigens include proteins and derivatives thereof, such 
as glycoproteins, lipoproteins and nucleoproteins and peptides. Fragments of such 
proteinaceous substances are also included within the term “antigen”. Preferably, such 
fragments consist o f or comprise antigenic determinants. Non-proteinaceous substances 
5 which are antigens include polysaccharides, lipopolysaccharides and nucleic acids. In 
particular, the term “antigen” includes nucleic acid molecules that induce an immune 
response against the proteins they encode. Fragments of such non-proteinaceous 
substances are also included with the tenn “antigen”. The term “antigen” further includes 
proteinaceous or non-proteinaceous substances linked to a earner which are able to induce 
10 an immune response, such as lipids or haptens upon which antigenicity is conferred when
they are linked to a carrier. The antigens o f the invention may be naturally occurring 
substances or may be synthesised by methods known in the art.
Where one purified antigen is used for immunisation, the antigen is preferably a 
proteinaceous substance or a nucleic acid molecule. Where the purified antigen is a 
15 proteinaceous substance, it may be introduced alone or in tire form o f a fusion protein. In
particular, the invention provides that the antigen may be in the form of a fusion protein 
expressed on the surface o f a recombinant virion with the animal being injected with the 
recombinant virion. The production of such recombinant virions using a nucleic acid 
sequence encoding the protemaceous antigen, is described in Lindley et al, 2000.
20 Where more than one purified antigen is used for immunisation, any combination of
purified antigens may be used. The animal may be injected with only proteinaceous 
antigens, only non-proteinaceous antigens, or a mixture of both. According to one 
embodiment of the invention, the purified antigens are all proteinaceous. The purified 
antigens may be fragments derived from the same protein or different proteins. The 
25 purified antigens may be recombinant virions derived from a cDNA library, each
recombinant virion expressing a protein encoded by a cDNA from the libraiy on its 
surface.
According to a further embodiment, the invention provides that multiple purified antigens 
are introduced into the animal in the form of nucleic acid molecules encoding proteins 
30 against which it is desired to produce monoclonal antibodies. The nucleic acid molecules
may be in DNA molecules, cDNA molecules or RNA molecules. Preferably, in this aspect 
of the invention, a eDNA library may be introduced into the animal. It is tlierefore possible
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to inject the animal with nucleic acid molecules encoding a protein o f unknown identity 
and as described below, cell chips may be used to isolate an antibody against the protein 
which in turn allows the protein to be purified.
Where the purified antigen is a nucleic acid molecule, it preferably consists o f or 
5 comprises a DNA, cDNA or RNA sequence encoding a protein against which an immune 
response is to be induced. The nucleic acid molecule may be a naked nucleic acid molecule 
or it may be in the form of a vector.
The vector may be a viral vector, preferably a retroviral, adenoviral, adeno-associated viral 
(AAV), herpes viral, alphavirus vector or any other suitable vector as will be apparent to 
10 the skilled reader. Alternatively, the nucleic acid molecule may be in the form of a non- 
viral vector, preferably a plasmid vector. Many such vectors are known and documented in 
the art (see, for example, Fernandez J.M. & Hoeffler J.P. in Gene expression systems. 
Using nature for the art o f expression ed. Academic Press, San Diego, London, Boston, 
New York, Sydney, Tokyo, Toronto, 1998). Such vectors may additionally incorporate 
15 regulatory sequences such as enhancers, promoters, ribosome binding sites and termination 
signals in the 5’ and 3’ untranslated regions of genes, that are required to ensure that the 
coding sequence is properly transcribed and translated.
Alternatively, the nucleic acid molecule may be in the form polycationic condensed DNA 
linked or unlinked to killed adenovirus alone, for example see Curiel (1992) Hum Gene 
20 Ther 3:147-154, or ligand linked DNA, for example see Wu (1989) J Biol Chem
264:16985-16987. The nucleic acid molecule may also be in the form o f DNA coated latex
beads. Alternatively, the nucleic acid molecule may be encapsulated in liposomes as 
described, for example, in W 095/13796, W094/23697, W091/14445 and EP-524,968. SA 
9I(24):11581-11585.
25 Antigen may be introduced into the animal by any suitable means. Preferably, the method
of introduction involves injection. The animals may be immunised with the purified
antigen or antigens intrasplenically, intravenously, intraperitoneally, intradermally or 
subcutaneously or by any other suitable means. The animals may be immunised with the 
purified antigen or antigens via more than one of these routes. For example, some of the 
30 purified antigen or antigens may be injected intraperitoneally and the rest subcutaneously. 
The means of injection will depend on the antigen or antigens being injected. For example,
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in the case of injection with a nucleic acid molecule a hand-held gene transfer particle gun, tas described in US 5,149,655 can be used to inject the nucleic acid molecule.
■1In the case o f a proteinaceous antigen, the dose of each antigen should preferably be in the 
range o f between 0.01 and 1000 micrograms.
Preferably, the method of the invention comprises the additional step o f supplying the
animal with a booster dose o f some or all of the antigens which are introduced into the |
animal prior to the recovery o f the antibody-producing cells. The animals may be given a 
booster 1-365 days after the first injection. Preferably, the animals are boosted 1 to 20 
times.
10 Preferably, tlie immunisation protocols used in the methodology o f the present invention 
are short where more than one antigen is used in order to prevent one antigen becoming 
immunodominant. Preferably, where the animal is immunised with more than one antigen, 
it is injected with a booster o f each antigen or combined booster o f more than one antigen 
3 days after the first injection and a further booster 5 days after the initial injection with 
15 spleen tissue or lymph nodes being removed between day 6 and day 15. Where a longer 
immunisation protocol is desired, the animal may be injected, for example, with a booster 
of each antigen or combined booster o f more than one antigen 21 days after the first 
injection, with the spleen tissue or lymph nodes being removed on day 26.
Immunisation o f the animal may be cairied out with or without pharmaceutical carriers. 
20 Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, 
polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, ammo acid 
copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus parti­
cles. Such carriers are well known to those of ordinary skill in the art. Additionally, these 
carriers may function as immunostimulating agents (“adjuvants”). Immunisation o f the 
25 animal may be carried out with or without adjuvants in addition to the pharmaceutical 
carriers.
Preferred adjuvants to enhance effectiveness of the composition include, but are not 
limited to: (1) aluminium salts (alum), such as aluminium hydroxide, aluminium 
phosphate, aluminium sulfate, etc; (2) oil-in-water emulsion fonnulations (with or without 
30 other specific immunostimulating agents such as muramyl peptides (see below) or bacterial 
cell wall components), such as for example (a) MF59™ (WO90/14837; Chapter 10 in 
Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press
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1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing 
MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAP, containing 
10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either 7
microfluidized into a submicron emulsion or vortexed to generate a larger particle size 
emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi hnraunochem, Hamilton, MT) 
containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components 
from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), ■''&
and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants,
■
such as QS21 or Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or 
10 particles generated therefrom such as ISCOMs (immunostimulating complexes), which 
ISCOMS may be devoid o f additional detergent e.g. WOOO/07621; (4) Complete Freund’s 
Adjuvant (CFA) and hicomplete Freund’s Adjuvant (IFA); (5) cytokines, such as 
interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (W099/44636), etc.), interferons 
(e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis 
15 factor (TNF), etc.; (6) monophosphoryl lipid A (MPL) or 3-0-deacylated MPL (3dMPL) 
e.g. GB-2220221, EP-A-0689454, optionally in the substantial absence o f alum when used 
with pneumococcal saccharides e.g. WOOO/56358; (7) combinations of 3dMPL with, for 
example, QS21 and/or oil-in-water emulsions e.g. EP-A-0835318, EP-A-0735898, EP-A- 
0761231; (8) oligonucleotides comprising CpG motifs (Roman et a l ,  Nat. Med., 1997, 3, 
20 849-854; Weiner et a l ,  PNAS USA, 1997, 94, 10833-10837; Davis et a l ,  J. Immunol, 
1998, 160, 870-876; Chu et a l, J. Exp. Med., 1997, 186, 1623-1631; Lipford et a l, Eur. J. 
Immunol, 1997, 27, 2340-2344; Moldoveanu et a l, Vaccine, 1988, 16, 1216-1224, Kiieg 
et a l,  Nature, 1995, 374, 546-549; KHnman et a l, PNAS USA, 1996, 93, 2879-2883; 
Balias et a l,  J. Immunol, 1996, 157, 1840-1845; Cowdery et a/., J. Immunol, 1996, 156, 
25 4570-4575; Halpem et a l. C ell Immunol, 1996, 167, 72-78; Yamamoto et a l, Jpn. J. 
Cancer Res., 1988, 79, 866-873; Stacey eta/., J. Immunol, 1996, 157, 2116-2122; Messina 
e ta l,  J. Immunol, 1991, 147, 1759-1764; Yi et a l,  J. Immunol, 1996, 157,4918-4925; Yi 
et a l,  J. ItnmunoL, 1996, 157, 5394-5402; Yi et a l, J. Immunol, 1998, 160, 4755-4761; 
and Yi et a l, J. Immunol, 1998, 160, 5898-5906; International patent applications 
30 WO96/02555, W 098/16247, WO98/18810, W098/40100, W 098/55495, W098/37919 
and W098/52581) i.e. containing at least one CG dinucleotide, with 5-methylcytosine 
optionally being used in place o f cytosine; (9) a polyoxyethylene ether or a 
polyoxyethylene ester e.g. W099/52549; (10) a polyoxyethylene sorbitan ester surfactant
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in combination with an octoxynol (WOO1/21207) or a polyoxyethylene alkyl ether or ester 
surfactant in combination with at least one additional non-ionic surfactant such as an 
octoxynol (WOOl/21152); (11) a saponin and an immunostimulatory oligonucleotide (e.g. 
a CpG oligonucleotide) (WO00/62800); (12) an immunostimulant and a particle o f metal 
5 salt e.g. WOOO/23105; (13) a saponin and an oil-in-water emulsion e.g. W 099/11241; (14)
a saponin (e.g. QS21) + 3dMPL + IL-12 (optionally + a sterol) e.g. W098/57659; (15) 
other substances that act as immunostimulating agents to enhance the effectiveness of the 
composition. Additional examples o f adjuvants that may be used include Montanide ISA 
50, Hunter’s TiterMax, and Gerbu Adjuvants.
10 Preferred antibody-producing cells for use in the invention include B cells, T cells and 
stem cells. These antibody-producing cells for use in the invention may be recovered by 
removal of any suitable cellular components o f the immune system from the animal. 
Preferably, antibody-producing cells are recovered from the animal by removal o f the 
spleen, lymph nodes or bone marrow or portions thereof. These may be rendered into a 
15 single cell suspension according to step b) o f the method o f the invention via any suitable
means. Preferably, spleen tissue, lymph nodes or bone marrow removed from the animal 
are rendered into a single cell suspension by mechanical disruption or enzymatic digestion 
with proteases. Red cells may be removed from the cell suspension by hypotonic lysis.
Preferably, the immortalized cell line specified in step c) o f the method o f the invention is 
20 a hybridoma cell line produced by somatic fusion of the cells in the single cell suspension 
to myeloma cells. Cells in the single cell suspension are fused to myeloma cells with a 
fusogen. Examples of myeloma cells which may be used include SP2, N Sl and NSO. 
Preferably, the fusogen is PEG, a virus or a method o f electrofusion (Zimmermann et al. 
1990).
25 The hybridoma cells produced by the fusion of the single cell suspension with the
myeloma cells should be cultured. Preferably, the hybridoma cells are initially cultured in a 
selective media, such as Azaserine hypoxanthine or Hypoxauthine aminopterin thymidine, 
and are then transferred to a non-selective media. Preferably, the hybridoma cells are 
cultured on selective media for 7 days and are then transferred to a non-selective media for 
30 3 days. This ensures that the growth rate of the cells increases prior to the screening step.
Preferably, the steps involved in hybridoma production are conducted robotically in order
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to speed up the process. The Examples set out one way of conducting the steps involved in 
hybridoma production robotically.
Alternatively, the immortalized cell line may be a cell line generated by infection o f cells 
hi the single cell suspension with an immortalizing virus. Preferably, tlie immortalizing 
5 virus is Epstein-Bar vims (see, for example, Epstein Ban- Vims Protocols, Eds. Wilson and
May, Humana Press; ISBN: 0896036901).
Step d) of the method of the invention comprises screening the supernatant o f the 
immortalized cell line, preferably a hybridoma cell Ihie, against a protein chip comprising 
a candidate antigen with which the animal was immunised. As used herein, the term 
10 “protein chip” is used to encompass any microarray made up o f a supporting means to 
which a candidate antigen has been anchored.
Where just one purified antigen has been introduced into the animal, that purified antigen 
and no additional antigens may be anchored on the protein chip. Where more than one 
purified antigen has been introduced into the animal, each purified antigen may be 
15 displayed at a different position on the protein chip, preferably at a predetermined position.
Each position on the protein chip may thus display a different antigen. Alternatively, the 
same antigen may be anchored to each position in a row or column of a protein chip with a 
different antigen being displayed in each row or column. Ei some cases, it may be 
desirable, even when the animal has been innnunised with more than one purified antigen, 
20 to have a different chip for each antigen. A protein chip may have a large number, such as
between 1 and 1000 purified antigens, anchored at predetennined positions on a chip.
Any type o f protein chip known in the art may be used in the method of invention. For 
example, the protein chip may be a glass slide to which the purified antigen or antigens are 
anchored. Where only one antigen is being tested, such a slide may be prepared simply by 
25 coating glass microscope slides with aminosilane (Ansorge, Faulstich), adding an antigen-
containing solution to the slide and drying. Slides coated with aminosilane may be 
obtained from Teleehem and Pierce for coating with the purified antigen. Preferably, such 
a glass slide may be coated with (6-aminohexil) aminosilane.
Other types o f protein chips which may be used in tbe method o f the invention include a 
30 3D gel pad (Arkenov et al, 2000) and microwell chips. As will be apparent to the skilled 
reader, types o f protein chips that have not yet been conceived but which are devised in the 
fliture may well prove to be suitable for use in accordance with the present invention.
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The term “protein chip” also includes inicroarrays o f cells expressing defined cDNAs 
(Ziauddin et al, 2001) referred to herein as “cell chips”. In tliis technique, mammalian cells 
are cultured on a glass slide printed in defined location with different cDNAs. Cells 
growing on the printed locations take up and express the cDNAs. Cell chips are 
5 particularly useful when the animal has been injected with a cDNA or a cDNA library or
with a recombinant virion or virions produced from a cDNA library, as described above. In 
such cases, the proteins encoded by the cDNA sequences may not have been isolated. By 
injecting the animal with cDNAs encoding the proteins or recombinant virions expressing 
the cDNAs, it is possible to produce monoclonal antibodies against the proteins expressed 
10 by the cDNAs. If the same cDNAs are expressed using a cell chip, these antibodies will
bind and the binding may be detected as described below. Providing that a nucleic acid 
sequence encoding the protein is available, the invention in this manner enables the 
detection and isolation o f a monoclonal antibody against that protein which may be used to 
purify the protein itself.
15 For selection o f antibodies, or selection o f immortalised cell lines producing such 
antibodies, the supernatant from the immortalised cell line or cell lines is spotted onto the 
protein chip or protein chips at defined positions on the chip. Spotting o f supernatants is 
preferably done robotically, for example with a Genemachines Ominigrid arrayer using 
Teleehem pins. Preferably, the supernatants spotted onto the protein chip or protein chips 
20 contain glycerol to minimise drying and fixing o f the antibodies on the slide. For example, 
0 to 99.9% glycerol may be used. The chip is then washed to remove any unbound 
supernatant. At this stage, any monoclonal antibody produced by the immortalized cell line 
and hence in the supernatant may be bound to an antigen on the chip.
By using different elution conditions, the method allows the approximate quantification of 
25 die binding affinity o f the monoclonal antibody for its binding partner. Elution agents that 
may be used include chaotropic agents such as guanidine hydrochloride or urea at 
concentrations between 10 pmolar and 8 molar or etiiylene glycol in an aqueous solution 
of 0.01% to 100% w/v. Elutions may also be carried out using aqueous or non-aqueous 
solutions o f glycine at concentrations of between O.Olmolar and a saturated solution 
30 (preferably 200mM), at a pH of between pH9 and pH 1, preferably pH3,2. High pH elutions 
may be carried out using aqueous or non aqueous solutions o f triethylamine between 
Ipmolar and a saturated solution, preferably lOOmM, at a pH o f between pH8 and pH 13, 
preferably pH 11.5.
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Step e) o f the method of the invention involves selection o f a monoclonal antibody that 
binds to the antigen. Preferably, this step incorporates a detection step, such as by adding a ' J
marker which will bind to bound monoclonal antibody and indicate its presence.
Preferably, the marker is labelled with a label such as an enzymatic or fluorescent label 
5 that enables its presence to be detected. For example, the marker may be labelled protein A
or labelled protein G. Protein A or protein G may be labelled with a fluorescent label such 
as Cy3 or Cy5. Alternatively, protein A or protein G may be labelled with an enzymatic 
label such as biotin, the presence o f which can be detected by the binding o f labelled 
strepavidin or avidin.
10 Preferably, the marker is an antibody that will bind to the first antibody. Preferably this
antibody is labelled with a label such as an enzymatic or fluorescent labels. Preferably this 
antibody is labeled with fluorescent labels as this enables equipment developed for 
scanning o f DNA chips to be used for detection.
Preferably, the step of detecting a monoclonal antibody bound to the antigen furtlier 
15 comprises isotyping the monoclonal antibodies. Preferably, this step of detecting and
isotyping the monoclonal antibodies comprises adding isotype-specifîc anti­
immunoglobulin antibodies to said protein chip, wherein each anti-immunoglobulin 
antibody having a different isotype specificity has a different label, and detecting the 
presence of said labels. This method enables the simultaneous detection of the monoclonal 
20 antibody and determination o f its isotype.
It will be appreciated that the method may employ as many different isotype-specific anti­
immunoglobulin antibodies, each with a different label, as there are antibody isotypes in 
the animal which has been immunised. For example, if  a mammal, such as a mouse, has 
been injected with an antigen, the step o f detecting and isotyping monoclonal antibodies 
25 bound to the antigen may comprise adding an anti-IgA antibody labelled with a first label,
and/or an auti-IgD antibody labelled with a second label, and/or an anti-IgE antibody 
labelled with a third label, and/or an anti-IgGl antibody labelled with a fourth label, and/or 
an anti-IgG2a antibody labelled with a fifth label, and/or an anti-IgG2b antibody labelled 
with a sixth label, and/or an anti-IgG3 antibody labelled with a seventh label, and/or an 
30 anti-IgG4 antibody labelled with a eighth label, and/or an anti-IgM antibody labelled with
a ninth label. Alternatively, the step o f detecting and isotyping monoclonal antibodies 
bound to the antigen may comprise adding isotype-specific anti-immunoglobulin
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antibodies that bind to a subset of the possible isotypes. Preferably, the isotype-specific 
anti-iinniunoglobulm antibodies comprise an anti-IgM antibody labelled with a first label 
and an anti-IgG antibody labeled with a second label Preferably, the labels are fluorescent 
labels.
. . . V :5 Detection o f the label indicates the presence o f a monoclonal antibody bound to an antigen f
and is preferably done robotically. Where the label is a fluorescent label, detection of the j:
label and hence the presence o f the monoclonal antibody may be done using equipment 
available for scaiming protein chips. For example, scamiing o f the chips may be done with 
a GenePix 4000B scanner (Axon Instruments, Lie.) or with a Tecan LS200 or LS400
10 scanner. Scanning may be carried out with between 1 and 4 lasers and combinations of
filters to enable visualisation o f multiple fluorescent labels. Preferably, visualisation of 
multiple fluorescent labels is carried out simultaneously although it may be carried out 
sequentially.
Images may be obtained and analysed using appropriate software such as the GenePix Pro 
15 software (Axon Instruments, Inc.), Chipskipper software (Schwager, Ansorge) or Tecan
LS200 or LS400 software.
In order to ensure that the detection o f a monoclonal antibody is reliable, the screening 
method preferably employs various controls. For example, in the case o f a protein chip 
coated with one antigen, not only will the supernatants fironi the immortalized cell lines 
20 produced by the method o f the invention be spotted onto the protein chip but so will
positive and negative controls.
Positive controls may be in the form of previously tested monoclonal antibodies or 
commercially available polyclonals. Alternatively, positive controls may consist of diluted 
or undiluted serum previously collected from the immunized mouse either a suitable period 
25 after the boost or at the moment the animal is sacrificed for the collection o f the source of 
B-cells,
Negative controls may be in the form of mock supernatants at defined positions. Another 
level o f control is determined by the fact that each supernatant is screened against several 
antigens. Signals obtained against only one antigen are considered to be potential positive 
30 monoclonal antibody containing supernatants.
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Positive signals on the protein chip can be traced back to a particular immortalised cell line 
enabling the monoclonal antibody to be isolated according to step e) o f the method o f the 
invention. Further characterisation of the antibodies identified can then be carried out.
Methods for carrying out further characterisation of the antibody may include, for example, 
5 the Anther step o f determining the specificity o f the monoclonal antibodies identified. For
example, a monoclonal antibody identified by the metliod o f the invention may be used to 
scan a second protein chip having a large number o f different proteins anchored to its 
surface to establish if the monoclonal antibody binds specifically to one antigen. The 
scanning methods described above in the initial identification o f the protein may be used to 
10 scan for its specificity. The binding specificity and affinity o f the monoclonal antibodies
produced by the method o f the invention may be further characterised by altering the 
concentrations of antigen on protein chips or altering the stringency of eluting conditions, 
as described above.
According to a further embodiment o f the first aspect o f the invention, there is provided a 
15 method for producing an immortalised cell line that produces a monoclonal antibody of 
interest, said method comprising the steps of;
a) introducing at least one candidate antigen into an animal;
b) recovering antibody-producing cells from said animal and rendering these cells into a 
single cell suspension;
20 c) generating an immortalized cell line from said single cell suspension;
d) screening the supernatant o f said immortalized cell line against a protein chip on which 
the candidate antigen is displayed; and
e) selecting as said immortalised cell line, tliat which produces a supernatant containing 
an antibody that binds to said candidate antigen.
25 Immortalised cell lines produced by such a method are of immense utility in the generation
of antibodies with tailored specificities.
According to a particular embodiment o f the first aspect o f the invention, there is provided 
a high-throughput method for producing a plurality of monoclonal antibodies, each of 
which binds to a different candidate antigen, comprising the steps of:
30 a) introducing a plurality o f candidate antigens into an animal;
b) recovering antibody-producing cells from said animal and rendering these cells into a 
single cell suspension;
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c) generating immortalized cell lines from said single cell suspension;
d) screening the supernatant o f said immortalized cell lines against one or more protein 
chips on which the candidate antigens are displayed; and
e) selecting as said monoclonal antibodies, antibodies that bind to said candidate antigens.
5 The candidate antigens are preferably purified candidate antigens, as described above.
Suitable procedures for introducing the candidate antigens into the animal, recovering
antibody-producing cells, generating immortalized cell lines and screening the supernatants 
of the immortalized cell lines are described above.
,/■Prior art methods involve laborious and time-consuming procedures to generate and screen 
10 for a monoclonal antibody against a single antigen. In contrast, this method enables the 
generation and high-tln-oughput screening of monoclonal antibodies against a plurality of 
antigens simultaneously. The use o f a protein chip to conduct high-throughput screening o f  
the antibodies is more efficient and more accurate than the use o f conventional assays and 
requires less candidate antigen.
15 Preferably, step e) o f this embodiment further comprises isotyping the monoclonal
antibodies, as described above. This provides an additional advantage over the prior art
methods which do not disclose simultaneous detection and isotyping of monoclonal
antibodies.
According to a second aspect o f the invention, there is provided a monoclonal antibody 
20 produced by a method o f the invention. The invention may also be used to generate a bank 
o f antibodies, for example, with specificities encompassing an entire organismic proteome.
Such a bank o f antibodies represents a further aspect of the invention.
According to a third aspect o f the invention, there is provided an immortalized cell line, 
preferably a hybridoma cell line, which produces a monoclonal antibody according to the 
25 second aspect o f the invention. This aspect o f the invention also includes a bank of 
immortalized cell lines, preferably a bank o f hybridoma cell lines. The invention may also 
be used to generate a bank o f hybridoma cell lines, for example, that produce antibodies 
encompassing an entire organismic proteome.
According to a fourth aspect o f the invention, there is provided a method for producing a 
30 plurality o f monoclonal antibodies, each o f which binds to a different purified candidate 
antigen, comprising introducing a plurality o f purified candidate antigens into an animal.
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Preferably, each candidate antigen is derived from a different source. By this is meant that 
each antigen is derived from a different protein, a different nucleic acid and so on. It is 
intended that methods of antibody production that involve injecting an animal with 
different fragments of the same protein are excluded from the scope of this aspect o f the 
5 invention. For example, tlie purified candidate antigens may all be proteinaceous
substances provided that they are not all fragments of the same protein.
This method has an advantage over methods disclosed in the prior art in that it enables the 
simultaneous production o f more than one monoclonal antibody, each of which binds to a 
different purified candidate antigen.
10 The animal may be injected with the purified candidate antigens usmg any o f the
techniques described herein. For example, the method of this aspect o f the invention may 
further comprise the steps o f recovering antibody-producing cells such as B cells, T cells 
and stem cells from an immunised animal, such as by removing spleen tissue, lymph nodes 
or bone marrow, and rendering them into a single cell suspension. The method may frirther 
15 comprise generating immortalized eell I hies, preferably hybridoma cell lines, from the cells
the single cell suspension. Preferably, the method of this aspect o f the invention comprises 
these steps and additionally comprises the steps of screening the supernatants of the 
immortalized cell lines, preferably hybridoma cell lines, against a protein chip or protein 
chips on which the candidate antigens are displayed; and selecting monoclonal antibodies 
20 that bind to the antigens and preferably isolating these and/or the immortalized cell lines
that produce the monoclonal antibodies. Suitable procedures for generating the 
immortalized cell lines and subsequent screening of the supernatants are the same as those 
described in above in connection with the method of the first aspect o f the invention. In 
particular, the step o f detecting the monoclonal antibodies may involve simultaneous 
25 detection o f the monoclonal antibodies and determination of this isotype, as described
above. In addition, the method may comprise further characterisation of the monoclonal 
antibodies, as described above.
The invention also provides a monoclonal antibody produced by a method of this aspect o f 
the invention. Again, this aspect o f the invention may be used to generate a bank of 
30 antibodies, for example, encompassing antibodies with specificity for protein in an entire
organismic proteome. Such a bank of antibodies represents a frirther aspect o f the 
invention.
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The invention also provides an immortalized cell line, preferably a hybridoma cell Ime, 
which produces a monoclonal antibody as described above. The invention may also be 
used to generate a bank o f  immortalized cell lines, preferably a bank o f hybridoma cell 
lines, for example, that produce antibodies encompassing an entire organismic proteome.
5 According to a fifth aspect of the invention, anti-idiotype antibodies may be generated that 
bind to a monoclonal antibody according to the second aspect o f the invention. Anti­
idiotype antibodies are useful as they have a variable region that mimics the shape o f the 
molecule to which the original antibody was raised. Anti-idiotype antibodies may therefore 
be useful in therapy as replacements for the molecules against which the original antibody 
10 was raised. An anti-idiotype antibody may be produced by employing the method o f the 
first aspect o f the invention or the fourth aspect o f the invention using a monoclonal 
antibody according to the second aspect of the invention as the purified candidate antigen.
Accordingly, this aspect o f the invention provides a method o f producing an anti-idiotype 
antibody that binds to a monoclonal antibody according to the second aspect of the 
15 invention, the method comprising using a monoclonal antibody according to the second
aspect of the invention as a purified candidate antigen in a method of the first aspect of the 
invention or the fourth aspect o f the invention. The invention also includes anti-idiotype 
antibodies generated by such methods.
According to a sixth aspect o f the invention, anti-anti-idiotype antibodies may be generated 
20 that bind to an anti-idiotype antibody produced according to the fifth aspect o f the
invention. Such anti-anti-idiotype antibodies may be produced by employing the method of 
the first aspect o f the invention or the fourth aspect o f the invention using an anti-idiotype 
antibody as described above as the purified candidate antigen. This aspect of the invention 
thus provides a method o f producing an anti-anti-idiotype antibody that binds to an anti- 
25 idiotype antibody generated according to the fifth aspect of the invention, the method 
comprising using an anti-idiotype antibody as described above as a purified candidate 
antigen in a method o f the first aspect o f the invention or the fomth aspect o f the invention.
Various aspects and embodiments o f the present invention will now be described in more 
detail by way o f example. It will be appreciated that modification of detail may be made 
30 without departing fi-om the scope o f the invention.
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Brief description of the Figures:
Figure 1 : Whole image of scanned chip, where green and red spots represent positive IgG 
and IgM producing supernatants respectively. Close ups are to show details o f specific 
ai eas o f chip where good spots are to be found.
5 Figure 2: Comparison between chip analysis and ELISA screen. First image is negative 
sample (la <0.5), while others are positive. Average Ic: Average total intensity of spot on 3 
chips. la: Average contribution o f spot to sum o f intensities over three chips (%).
Figure 3: Comparison of contribution to total intensity (%) of cultm e supernatants screened 
by ELISA (■) or by chip analysis (□) for binding to B5 gntigen (Figure 3A). The 
10 background values are shown in Figure 3B. A number of positive supernatants identified 
by chip analysis and/or ELISA are shown.
Figure 4: Comparison o f contribution to total intensity (%) of culture supernatants screened 
by ELISA (■) or by chip analysis (□) for binding to B5 antigen (Figure 4A). The 
background values are shown in Figure 4B. A single positive supernatant identified by chip 
15 analysis and ELISA is shown.
Figure 5: Comparison of contribution to total intensity (%) of culture supernatants screened 
by ELISA (■) or by chip analysis (o) for binding to Ket94/95 antigen (Figure 5A). The 
background values are shown in Figure 5B. A number of positive supernatants identified 
by chip analysis and/or ELISA are shown.
20 Figure 6: Comparison of contribution to total intensity (%) of culture supernatants screened
by ELISA (■) or by chip analysis (□) for binding to Ket94/95 antigen (Figure 6A). The
background values are shown in Figure 6B. No positive supernatants were identified by 
either ELISA or chip analysis.
25 Examples
Example 1: Immunization with 10 protein antigens 
Immunization
An 8-week old female Balb/c mouse was injected intrasplenically with 10 |ig o f each o f 10 
protein antigens in lOOjll phosphate buffered saline (PBS). On the third day following (day 
30 3) the mouse was injected intraperitoneally with lug o f each of the same 10 protein
antigens in lOOpl PBS. On day 5, the same mouse was injected intravenously with 0.1 pg
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of each o f the same 10 protein antigens. On Day 8 the mouse was killed by cervical 
dislocation and the spleen removed and eollected into Dulbecco’s Modified Eagle’s 
Medium (DMEM: Life Technologies Inc.).
Fusion
5 All steps are performed under sterile or aseptic conditions in a laminar flow hood. The 
spleen was rendered into a single-cell suspension by mechanical disruption between two 
Ifosted-end glass microscope slides. The suspension was filtered into a 50ml bar-coded 
conical-bottomed tube (BD Falcon) through a 70p.m nylon cell strainer (BD Falcon) and 
transferred to the robotic system.
10 Separately, SP2 myeloma fusion partners (ATCC) were cultured for five days prior to 
fusion in HM20 (DMEM, 20% Defined fœtal bovine serum (Hyclone Defined), lOmM L- 
Glutamine, 50|iM Gentamicin) and on the day o f the fusion were transferred to 
HM20/HCF/2xOPI (HM20 containing 10% Hybiidoma Cloning Factor (Origan) and 
2%0PI cloning supplement (Sigma)) for at least one hour at 37‘’C in a 5% CO2 incubator.
15 The bar codes were read by a bar code reader and the 50ml Falcon tube loaded into the 
rotor by the RoMa arm on the genesis Freedom system (Tecan). The rotor was loaded into 
the centrifuge tluough the workdeck.
The tube was centrifuged at lOOg for 10 mins at room temperature (RT) and the rotor 
extracted from the centrifuge. The tube was extracted from the rotor and the bar code was 
20 again read to distinguish from the balance tube. Cells were resuspended in 5ml Red Cell
Lysis Buffer (Sigma) for 9 minutes at RT. HM20 was added to 50ml and the tube once 
again centrifuged for 10 min at RT with no brake. The supernatant solution was aspirated 
to waste and the cells resuspended in DMEM preheated to 37°C. Cells were washed twice 
more by steps of centrifugation and resuspension. 50p,l o f cell suspension were robotically 
25 pipetted to a 1.5ml microcentrifuge tube. Cells were counted using a haemocytometer 
counting chamber.
Simultaneously the SP2 cells were washed three times in a similar fashion and a similar 
aliquot (50)0.1) “handed o f f ’ to a 1.5 ml tube for haemocytometric counting. SP2 myelomas 
and spleen cells were mixed at a ratio o f 1:5 (SP2:Spleen) and again centiifuged at lOOg 
30 for 10 min with no brake.
:
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On the third day following the fusion cells were robotically transported from the incubator 
25 to the work deck and a further lOOfil HM20/HCF/OPI/AH was robotically added. The 
plates were then robotically returned to the incubator.
On day 7 the plates were once again similarly transported from incubator to work deck and 
200|il/well o f culture supernates was aspirated to waste and replaced with 150pl fresh 
HM20/HCF.
19
The supernatant solution was entirely aspirated to waste and Polethyleneglycol 1500 in 
50% HEPES (PEG: Roche Molecular Biochemicals) pre-heated to 37°C was robotically 
pipetted smoothly and progressively over 1 min with rotation at 450rpm on a Te-shake ï
shaker (Tecan AG) to ensure even mixing. The cell/PEG mixture was incubated for 1 min 
5 at 37“C with gentle agitation. 1 ml of DMEM was similarly added over 1 min at 37°C with 
similar agitation. The mixture was incubated for 1 min at 37°C with gentle agitation. A 
further 1ml o f DMEM was robotically added over 1 min at 37°C with gentle agitation and 
incubated similarly for a further minute. 7mls o f FIM20 were robotically added over 3 min 
at 37°C with gentle agitation. The Tube was then spun at 90g for 5 min with brake. The 
10 supernate was aspirated to waste and the pellet resuspended in 20ml of 
ITM20/FICF/OPI/AFI (HM20/HCF/OPI plus 10% Azaserine Hypoxanthine (Sigma).
The conical tube was again placed on the robot workdeck and the post-fusion cell sluiry 
was aspirated by each of the 8 wide-bore pipette tips o f the liquid handling arm of the 
robot. 200pl o f the cell slurry was then pipetted into each well o f a 96-well deep well plate 
15 (Greiner Masterblock).
The deep-well plate was then robotically transferred to a TeMo 96-well pipetting robot 
integrated onto the Genesis work-deck and used as a source plate to plate out into the 20 
sterile 96-well tissue culture plates.
The post-fusion mixture was then robotically plated out into 20 96-well sterile plates 
20 (Nunc) sourced from a carousel attached and integi'ated to the robot at lOOpl/well and 
robotically transferred to an integrated 37°C incubator with 10% CO2 through the 
integrated airlock. Plates were stored in a carousel contained with the incubator.
Cell Culture
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On day 11 the plates were again robotically transported to the work deck and 30|al of 
supernate was collected from each well (Temo head: Tecan Inc.) and transferred to 384- 
well plates supplied to the workdeck by a carousel plate stacker (Tecan Inc).
Microarray screening
5 Aminosilane coated glass slides were homogeneously coated with purified antigen by ' {dropping 40|il of ddl-^O containing 1-5 jig of antigen and covering with a 22*60mm 
coverslip for 60min in a humid chamber at RT.
Coated slides were rinsed briefly in PBS and blocked for 60’ in 5% milk in PBS, 0.1% ■:ïTween, then washed for 10’ in PBS. The chips were then dried by centrifogation, 10” at 
10 2000 rpm.
Culture supernatants were consolidated into 384 well plates using a Beckman Biomek FX 
robot.
Culture supernatants were printed singularly onto three identical antigen-coated slides at a 
density of 9600 spots per chip and a spot size o f -120|lm  using a GeneMachines OmniGrid 
15 microarray printer.
The microarray chips were incubated in a humid chamber for 60’, at RT and then washed 5 
X 5’ in PBS-0.1% Tween (PBST)
40|rl o f Cy3 conjugated goat anti-mouse IgG-specific and Cy5 conjugated goat anti-mouse 
IgM-specific antibodies were diluted 1:1000 in PBST, mixed and applied uniformly to the 
20 chips and covered with 22x60 mm coverslips and incubated in a humid chamber, for 30’ at 
RT, The chips were then washed 2 x 10’ in PBST, 2 x 10’ in PBS and 1 x 10’ in ddH^O.
The chips were dried by centrifugation at 2000 rpm for 10”,
Hit-Picking
Chips were scanned with a GenePix 4000B scanner (Axon Instruments), at a resolution of 
25 10 um.pixef'. PMT voltages were 540V and 610V, for the Cy3 and Cy5 channels
respectively. Both lasers were set at 100% intensity. Each scanned chip was assigned a 
fitted grid, and all spots were analysed by the GenePix Pro 3.0 (Axon Instruments).
All chips were analysed by the GenePix Pro 3.0 software and we collected, for each chip, 
the information relative to the corrected intensity (L) of each spot (Median o f intensities —
30 Background), for the Cy3 and Cy5 channels. From this data, we obtained, for each chip.
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the contribution o f each spot to the total Corrected Intensity o f each channel 
f
xlOO). The three values of each chainiel were averaged for each spot, and£ 9600 j  
I %
this Average Corrected Intensity (L) was used for the final analysis of the dataset. We 
considered as “likely to be positive” samples the ones that have a value above 0.5% and as 
5 “sure positives”, all the samples showing a value superior to 1.5%.
Post Screening Processing
Cells from positive wells were resuspended in the well and 20|al transferred to a 96-deep- 
well plate previously filled with 1.5mls o f HM20/HCF and returned to tlie incubator for 
48hi-s at 37°C, 5%CÛ2.
10 1.4ml o f culture each supernate was transferred to another deep well plate and the
remaining lOOjil used to resuspend the cells which were then transferred to a freezing vial 
containing 90% Fœtal bovine semm/10%DMSO (Sigma) and transferred to -80°C for 2hrs 
and from there to liquid nitrogen store. Culture supernate was then used for evaluation and 
frirthcr characterization o f the generated monoclonal antibody.
15 Results:
The results of microarray screening are shown in Figure 1. This Figure demonstrates that a 
number of positive monoclonal antibodies were detected as binding to candidate antigens 
on the slide. The green spots are IgG monoclonal antibodies which bind to the candidate 
antigens while the red spots are IgM monoclonal antibodies which bind to the candidate 
20 antigens. Figure 1 thus demonstrates that the method o f the invention can be used to
simultaneously identify monoclonal antibodies that bind to the candidate antigens and the 
isotypes of those monoclonal antibodies.
When a comparative experiment was conducted using ELISA in the place o f a protein 
chip, a number o f monoclonal antibodies identified as binding to candidate antigens in the 
25 microaiTay screening were not identified as binding to candidate antigens using ELISA, as
shown in Figure 2 (see comparison o f microarray results with ELISA results). A 
supernatant which was found to be negative using microarray screening (Ia:0.234) was also 
found to be negative using ELISA. However, o f four supernatants found to be positive 
using microanay screening (la: 5.18, 1.96, 3.64 and 2.02), only two were found to be 
30 positive using ELISA (see Figure 2). It is important to note how the supernatants that were
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negative in the ELISA experiment can be actual positive samples as detected by the more 
accurate and sensitive microarray approach.
Example 2: Immunization with nine antigens 
Immunization:
5 A mouse was injected with 25pg o f nine antigens, including 25pg of a fusion o f the 
antigens B5 and Ket94/95, each antigen being mixed with lOpg CpG DNA and adsorbed 
onto alum adjuvant (Imject Alum from Pierce). Half o f each antigen was administered 
intraperitoneally and half subcutaneously.
The mouse was boosted 21 days later with lOpg of each antigen mixed with lOpg o f CpG |
10 DNA and adsorbed onto alum adjuvant, half of which was administered intraperitoneally 
and half subcutaneously.
Five days after the boost, the spleen was removed.
Fusion and cell culture
The fusions and cell culture were performed as described in Example 1.
15 Microarray screening of antibodies against B5 and Ket94/9S
An aminosilane glass slides was homogenously coated with purified B5 by dropping 40pl 
of ddH20 containing 5pg o f puiified B5 and covering with a 22*60mm coverslip for 60 
min at room temperature. The same procedure was used to produce an aminosilane glass 
slide homogenously coated with purified Ket94/95.
20 The coated slides were rinsed, blocked, washed and dried, as described in Example 1, 
except that 3% BSA in PBS was used in place o f 5% milk in PBS to block the slide.
Culture supernatants were consolidated into 384 well plates, as described in Example 1 and 
were printed in triplicate onto the slide coated with B5 and the slide coated with Ket94/95 
at a density o f around 16000 spots per chip and a spot size of-150p.m using a Microgrid II 
25 610 microarray printer (ApogenlDiscoveries).
The microarray chips were incubated and Cy3 conjugated goat anti-mouse IgG-specific 
and Cy5 conjugated goat anti-mouse IgM-specific antibodies were applied to the chips as 
described in Example 1.
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each supernatant to be screened multiple times against an antigen and uses only a fraction 
of the amount of antigen required for a single screening in a conventional screening assay 
such as an ELISA. For example, each supernatant can be screened in duplicate, triplicate or 
5 quadruplicate against an antigen.
The animal in step a) o f the method o f the invention may be any non-human mammalian j
animal. Preferably, the animal is a mouse, rat, rabbit, hamster or guinea pig. Preferably, the 
animal is a mouse.
The candidate antigen in step a) is preferably a purified candidate antigen. Either a purified 
10 candidate antigen or a mixture o f purified candidate antigens may be intioduced into the
animal. By “purified candidate antigen” is meant that the antigen is a homogenous 
preparation o f antigen that is substantially free from any other components. By “a mixture 
of purified candidate antigens” is meant that more than one purified antigen is present in 
the composition used for immunisation, but that the preparation is free from contaminating 
15 components for which there is no intention to elicit the production of antibodies. For 
example, although using conventional procedures, an animal may be immunised with 
multiple antigens simply by immunisation with homogenised tissue, such immunisation 
does not represent immunisation with purified candidate antigens as this is defined herein, |
since the antigens would be contaminated with cellular debris.
20 Any number o f purified candidate antigens may be intioduced into the animal. Preferably,
between 1 and 50 purified candidate antigens are introduced into the animal. Preferably, 
more than one purified candidate antigens are introduced into the animal. For example, 2,
3 ,4 , 5, 6, 7, 8, 9, 10, 15, 20, 30,40, 50 or more than 50 purified candidate antigens may be 
introduced into the animal. The antigens may be introduced simultaneously, in the sense 
25 that they are all mixed together. Alternatively, the antigens may be introduced separately 
one after the other. The introduction o f different antigens may be separated by a time 
period of days. Preferably, the period separating the introduction of different antigens is 
less than 48 hours, preferably less than 24 hours. Preferably, the method o f introduction 
involves injection o f the antigen(s) into the animal.
30 By the term “candidate antigen” is meant any substance capable o f inducing an immune 
response in an animal when that candidate antigen is introduced into the animal. The term 
therefore includes proteinaceous substances and non-proteinaceous substances.
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It is clear from these results that microanay screening is at least as effective as ELISA at 
identifying monoclonal antibodies that bind a specific antigen. Indeed the identification of 
positive supernatants not identified by ELISA suggests that microanay screening is more 
sensitive than ELISA. Microarray screening further had the significant advantage that it 
5 allowed simultaneous determination o f the IG or IgM isotype o f the monoclonal antibodies 
identified.
Figure 3A shows the noimalised values o f percentage contribution to total intensity for 
each culture supernatant in an ELISA plate (■) containing positive samples that bind B5 
compared to the normalised values o f percentage contribution for the same culture 
10 supernatants obtained by raicroarray screening of a B5-coated slide (□). Figure 3B shows 
the level o f background noise in these experiments. It can be seen that positive 
supernatants showed a greater percentage contribution to total intensity using microarray 
screening compared to ELISA. As a result, there was a greater difference between 
background noise and a positive supernatant in microanay screening compared to ELISA, 
15 enabling positive supernatants to be identified more easily and more accurately.
Figure 4A compares the normalised values o f percentage contribution to total intensity for 
each culture supernatant in an ELISA plate (■) containing a single positive sample that 
binds B5 compared to the normalised values o f percentage contribution for the same 
culture supernatants obtained by microarray screening on a B5-coated slide (□). The level 
20 of background noise is shown in Figure 4B and it can be seen that positive sample was
more readily detectable above the background noise using microarray screening compared 
to ELISA.
Figure 5A compares the normalised values of percentage contribution to total intensity for 
each culture supernatant in the ELISA plate found to contain positive supernatants that 
25 bind KET94/95 (■) compared to the normalised values of percentage contribution for the
same culture supernatants obtained by microarray screening on a KET94/95-coated slide 
(□). The positive supernatants were more readily detectable above the background noise 
using microairay screening compared to ELISA, as shown in Figure 5B.
Figures 6A compares the data obtained fiom an ELISA plate (■) in which there were no 
30 positive supernatants to data obtained using microarray screening (□) of the same culture
supernatants. As shown in Figure 6B, the readings in both cases were due to background 
noise.
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These results demonstrate that the method of the invention can be used to simultaneously 
identify monoclonal antibodies against more than one antigen. The use of microarray 
screening in the method o f the invention is quicker, cheaper and more accur ate than the use 
of conventional antibody screening methods, such as ELISA.
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Claims
1. A method for producing a monoclonal antibody, said method comprising the steps of:
a) introducing at least one candidate antigen into an animal;
b) recovering antibody-producing cells from said animal and rendering these cells into
5 a single cell suspension;
c) generating an innnortalized cell line from said single cell suspension;
d) screening the supernatant o f said immortalized cell line against a protein chip on 
which the candidate antigen is displayed; and
e) selecting as said monoclonal antibody, an antibody that binds to said candidate
10 antigen.
2. The method o f claim 1 wherein said animal is a mouse, a rat, a guinea pig or a rabbit.
3. The metliod of claim 1 or claim 2 wherein said candidate antigen is a purified 
candidate antigen.
4. The method o f claim 3 wherein between one and fifty different purified candidate 
15 antigens are introduced into the animal.
5. The method of claim 4 wherein between 0,001 and 1000 micro grams of each antigen is 
introduced into the animal.
6. The method o f any one o f claims 1 to 5 comprising the additional step of supplying the 
animal with a booster dose of some or all of the antigens which were introduced into
20 the animal prior to the removal o f antibody-producing cells.
7. The method of any one of claims 1 to 6 wherein the antibody-producing cells are B 
cells, T cell or stem cells.
8. The method o f any one o f claims 1 to 7 wherein the antibody-producing cells are 
recovered by removal o f spleen tissue, lymph nodes or bone marrow of the animal.
25 9. The method o f any one o f claims 1 to 8 wherein the immortalized cell line is a
hybridoma cell line produced by somatic fusion of the cells in the single cell 
suspension to myeloma cells.
10. The method o f any one o f claims 1 to 9 wherein said protein chip is a plain-glass slide, 
a 3D gel pad chip, a microwell chip or a cell chip.
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11. The method o f any one of claims 1 to 10 wherein the step of detecting the monoclonal 
antibodies bound to the antigens further comprises isotyping the monoclonal 
antibodies.
12. The method o f claim 11 wherein said step o f detecting and isotyping the monoclonal 4
5 antibodies comprises adding isotype specific anti-immunoglobulin antibodies to said
protein chip, wherein each anti-immunoglobulin antibody having a different isotype
specificity has a different label, and detecting the presence o f said labels.
.3
13. The method o f any one of claims 1 to 12 further comprising assessing the specificity 
with which each isolated monoclonal antibody binds to an antigen using a protein chip
10 comprising said antigen.
14. A high-throughput method for producing a plurality o f monoclonal antibodies, each o f  
which binds to a different candidate antigen, comprising the steps of:
a) introducing a plurality o f candidate antigens into an animal;
b) recovering antibody-producing cells from said animal and rendering these cells into a 
15 single cell suspension;
c) generating immortalized cell lines from said single cell suspension;
d) screening the supernatant o f said immortalized cell lines against one or more protein 
chips on which the candidate antigens are displayed; and
e) selecting as said monoclonal antibodies, antibodies that bind to said candidate antigens.
20 15. A method according to claim 14, which further comprises any of the steps recited in
any one o f claims 1 to 13.
16. A method for producing an immortalised cell line that produces a monoclonal antibody 
of interest, said method comprising the steps of:
a) introducing at least one candidate antigen into an animal;
25 b) recovering antibody-producing cells fr om said animal and rendering these cells into 
a single cell suspension;
c) generating an immortalized cell line from said single cell suspension;
d) screening the supernatant o f said immortalized cell line against a protein chip on 
which the candidate antigen is displayed; and
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e) selecting as said immortalised cell line, that which produces a supernatant 
containing an antibody that binds to said candidate antigen.
17. An immortalised cell line isolated by the method of claim 16.
18. A method for producing a plurality o f monoclonal antibodies, each o f which binds to a 
different purified candidate antigen, comprising introducing a plurality o f purified 
candidate antigens into an animal, each purified candidate antigen being derived from a 
different source.
119. A method according to claim 18 which further comprises any o f  the steps recited in any 
one o f claims 1 to 13.
10 20. A monoclonal antibody isolated by the method of any one o f claims 1 to 16 or 18 to 19.
21. An antibody according to claim 20 which is an anti-idiotype antibody.
22. An antibody according to claim 21 which is an anti-anti-idiotype antibody.
23. An immortalized cell line producing a monoclonal antibody o f claim 20, claim 21 or 
claim 22.
15 24. An immortalized cell accordmg to claim 23 which is a hybridoma cell line.
25. A bank o f antibodies according to claim 20, claim 21 or claim 22.
26. A bank o f immortalized cell lines according to claim 15, claim 21 or claim 22.
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Abstract
The present invention relates to methods for producing monoclonal antibodies. In 
particular, the invention relates to high tluoughput methods for producing and screening 
monoclonal antibodies more rapidly than conventional methods.
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FIG. 2
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8 Contents of the enclosed CD
A CD containing a working version of Hy-CAT is enclosed with this manuscript. The 
software has been tested with Windows 98 and 2000. To use the software, copy all 
contents of the CD into a new directory (eg: c:\Hy-CAT) and launch Setup.exe
8.1 Preparation of the plate definitions
To prepare a new set of plate definitions, select "Experiment ->  MakelDs” from the 
menu bar:
• Enter the number of 96 well plates to be consolidated into 384 well plates:
V M
Click on the "Fill 96 well plates" button. This will populate the table as described 
in Section 7.1 (page 103). It is possible to change the ID of individual wells (new 
ID or mark as "empty”) by clicking onto the desired well:
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if# ikUafccMl
When ready, click on the "Consolidate Plates" button, enter a filename in the 
"Save file" dialog box. The created file will be ready to be used by any spotting 
software to generate a chip definition grid:
flBBBl 
c u *
I ■ iK '-f»,'» 1 ! ■ * * * ,  j  : â » D t  I3UW
t^âÔOH 1ft VjiUatxiwkF:^
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8.2 Chip analysis
Data analysis can be done by selecting the "Experiment ->  New” menu item.
Click next on the first screen:
i ta  <1 O  iVÊSM _____ 4##"4 h < - " jJâtÜMf* t«»w. •* m#
Welcome to the lIj'-CAT,Ilybricore's CliJp Anal)%is Tool
WAW warl, imiMÏ* t»' W* I# pmtMttn imMIW IU
ntHTim pS»
Figure 30. Data analysis: Step 1
Fill the "antigen description” fields:
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General Parameters Window
( •
FMllWWllS MB)
t u v x m  ! n n  ^ • v u f . ' i i x u M i t n tUUi W» i.
Select the spotting parameters:
«ht.*» c«inBSHHHBT
Parameters Wlndos%
M w a w  I n « IVuHa
Select the required normalisation protocol:
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NomializAtlon W indow
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Insert filtering parameters and selection methods:
A
. I « •  Kir* IWurKi.
Select and load data file:
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Select the data fields for the analysis and click the "Go " button to start the calcu­
lations:
When the calculations have been completed, a histogram of the distribution of 
intensities is presented. Click any histogram bar to use that value as a selection 
threshold and obtain the IDs of all hybridomas showing an intesity greater than 
the chosen threshold. These selected hybridomas are displayed in an HTML 
page, divided by isotype (IgM: Red, IgG: Green)
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8.3 Selection of "Unique" samples
When more than one antigen have been screened in a single experiment, possible false 
positive, "sticky" or cross reactive antibodies have to be detected and eliminated from 
the result lists. For this purpopse, HyCAT generates text files containing the selected 
IgG and IgM antibodies after each screening procedure. This files are needed for the 
detection of unique samples. From the menu bar, select "Experiment ->  FindUniques".
• Click on the "Load the results files” button and select the required files to be 
analysed:
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• Enter a FusionID in the text box and click on the "Get them b..." button. All the 
"unique” samples will be displayed in antigen specific tables in an HTML file.
stÊti imwà
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This Thesis was written using LyX 1 .3.2 powered by T^X version (Web2C 7.4.5) 3.14159, 
running on a SuSe 9.0 platform.O Aopen source
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